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ABSTRACT
Accumulating evidence, in human and experimental animal models, show 
that kinins, notably bradykinin (BK) and kallidin, have cardioprotective 
effects. To these include reduction of left ventricular hypertrophy (LVH) and 
progression of heart failure. Their effects are mediated through two G protein-
coupled receptors- bradykinin type-2 receptor (BK-2R) and bradykinin 
type-1 receptor (BK-1R). The cardioprotective effects of BK-receptors relate 
to triggering the production and release of vasodilating nitric oxide (NO) by 
endothelial cells. They also exert anti-proliferative effects on fi broblasts and 
anti-hypertrophic effects on myocytes, and thus may play an essential role 
in the cardioprotective response to myocardial injury. The cardioprotective 
role of BK-2Rs is widely accepted. The role for BK-1Rs in HF, is based 
on experimental animal models, where the receptors have been linked to 
cardioprotective- but also to cardiotoxic -effects. The BK-1Rs are induced 
under infl ammatory and ischemic conditions. The induction has been shown 
in animal models; no previous reports, concerning BK-1Rs in human heart 
failure, have been presented.
Previously, it has been shown, that the expression of cardioprotective 
BK-2Rs were down-regulated in human end-stage heart failure. Present 
results showed that, in end-stage heart failure patients, the BK-1Rs were up-
regulated, suggesting that also BK-1Rs may be involved in the pathogenesis of 
human heart failure. The receptors were localized mainly in the endothelium 
of the intramyocardial coronary vessels, and correlated with the increased 
TNF-α expression in the myocardial coronary vessels. Moreover, in cultured 
endothelial cells, it was shown, that TNF-α is a potent trigger of BK-1Rs. 
These results suggest, that cytokines, such as TNF-α may be responsible for 
the up-regulation of BK-1Rs in human heart failure.
A linear relationship was discovered between BK-2R mRNA and protein 
expression in normal and failing human left ventricles, implying that 
the BK-2Rs are regulated on the transcriptional level, at least in human 
myocardium. The expression of BK-2Rs correlated positively with age 
in normal and dilated hearts (IDC), though the increase in receptors was 
clearly lower in dilated hearts. The results suggest, that human hearts adapts 
to age-related changes, by up-regulating the expression of cardioprotective 
BK-2Rs. It was also presented, that in the promoter polymorphism -58 
T/C, the C-allele was accumulated in cardiomyopathy patients which 
may partially explain the reduced number of BK-2Rs, in these patients.
The BK-receptors seem to contribute to the pathogenesis of human heart 
failure and they localize mainly in the endothelium of the myocardial coronary 
vessels.
ABSTRACT
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Statins are cardioprotective drugs, which reduce the level of plasma 
cholesterol, but also exert several non-cholesterol-dependent effects. The 
effects of statins were studied in human coronary arterial endothelial cells 
(hCAEC) and incubation with lovastatin induced both BK-1 and BK-2Rs in a 
time and concentration-dependent way. Moreover, the induced BK-2Rs were 
functionally active, thus NO production and cGMP signaling was increased. 
The induction was abrogated by mevalonate, a direct HMG-CoA metabolite. 
Lovastatin is known to inhibit Rho activation, and by a selective RhoA kinase 
inhibitor Y27632, we showed a similar induction of BK-2R expression as with 
lovastatin. Interestingly a COX-2-inhibitor NS398 inhibited this lovastatin-
induction of BK-2Rs, suggesting that COX-2 inhibitors may affect the 
endothelial BK-2Rs, in a negative fashion.
Hypoxia is a common denominator in HF but also in other cardiovascular 
diseases. An induction of BK-2Rs in mild hypoxic conditions was shown 
in cultured hCAECs, which was abolished by a specifi c BK-2R inhibitor 
Icatibant. These receptors were functionally active, thus BK increased and 
Icatibant inhibited the production of NO. In rat myocardium the expression 
of BK-2R was clearly increased in the endothelium of vessels, forming at the 
border zone, between the scar tissue and the healthy myocardium. Moreover, 
in in vitro wound-healing assay, endothelial cells were cultured under hypoxic 
conditions and BK signifi cantly increased the migration of these cells and as 
Icatibant inhibited it. These results show, that mild hypoxia triggers a temporal 
expression of functionally active BK-2Rs in human and rat endothelial cells, 
supporting a role for BK-2Rs, in hypoxia induced angiogenesis.
Our and previous results show, that BK-Rs have an impact on the 
cardiovascular diseases. In humans, at the end stage of heart failure, the 
cardioprotective BK-2Rs are down-regulated and BK-1Rs induced. Whether 
the up-regulation of BK-1Rs, is a compensatory mechanism against the down-
regulation of BK-2Rs, or merely refl ects the end point of heart failure, remains 
to bee seen. In a clinical point of view, the up-regulation of BK-2Rs, under 
hypoxic conditions or statin treatment, suggests that, the induction of BK-
2Rs is protective in cardiovascular pathologies and those treatments activating 
BK-2Rs, might give additional tools in treating heart failure.
Liesmaa_Inka_Vaitosk.indd   12 12.1.2010   19:17:05
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REVIEW OF THE LITERATURE
1. Heart Failure
1.1 Heart Failure – General
Heart failure (HF) is traditionally viewed as a hemodynamic syndrome 
characterized by fl uid retention, high venous pressure, and low cardiac output. 
It is usually, but not always, caused by a defect in myocardial contraction 
– myocardial failure – and it is a principal complication of virtually all forms 
of heart disease (93). The failing heart presents abnormal growth responses 
– namely myocyte hypertrophy, progressive remodeling and increased 
myocardial fi brosis. These structural abnormalities, which now are recognized 
to play a central role in determining the poor prognosis in this clinical 
syndrome, result from changes in the size, shape, and molecular composition 
of both cardiac myocytes and non-myocytes (221).
The major causes of HF are coronary heart disease (CHD), hypertension, 
and valvular diseases, which account for over 80% of the underlying causes. 
Other causes include entities such as diseases of the myocardium (myocarditis, 
cardiomyopathies) and pericardium, diseases of the lung and pulmonary 
vasculature, arrhythmias, and other diseases such as hyperthyreosis, alcohol 
abuse and diabetes.
During the last decades the understanding and treatment of heart failure has 
changed dramatically. Large, randomized clinical trials in the 1980s revealed 
the poor prognosis of HF patients and changed the view of HF being merely 
a hemodynamic disorder (220). It has now been realized that changes in the 
structure and composition of the myocardium play a key role in determining 
the survival of these patients (220). Patients often remain asymptomatic or 
minimally symptomatic after initial pump dysfunction has been present for 
many years. The progression of HF is related to the progression of underlying 
diseases, neurohumoral abnormalities, and LV remodeling (93). 
Heart failure is an increasing cause of morbidity and mortality in the Western 
world (15). Despite improved treatment and a relative reduction in mortality, 
the prognosis remains poor. The 5-year survival rate of all HF patients is only 
50%, and it is even worse in the more severe cases (15).
The prevalence of heart failure in Europe varies between 0.4% and 2.0% 
(95). It increases dramatically with age, being 1-2% for persons aged 50-59 
years and 6-8% for individuals over 75 years old (93). The mean age of the 
heart failure population in Europe is 74 years (485). Thus, HF is the leading 
hospital discharge diagnosis in patients over 65 years old and the prevalence is 
increasing, which is shown by the 55% increase in the number of hospitalizations 
1. HEART FAILURE
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due to HF between 1985 and 1995 (93). Fifteen million individuals in Europe 
and about fi ve million in America (2.2% of the population) currently have HF 
and 550 000 patients are diagnosed with HF annually (138;420).
The clinical manifestations of heart failure depend on the rate at which the 
syndrome develops and specifi cally on whether suffi cient time has elapsed 
for compensatory mechanisms to develop. Chronic HF can be described 
as a progressive disease where acute HF episodes with repetitive hospital 
admissions disrupt the normal progression of the disease. 
Since the Framingham study, there have been efforts to improve the 
prognosis of HF and the treatments have indeed improved. Before ACE 
inhibitors, the treatment of HF consisted of merely relieving the symptoms 
with diuretics and nitrates. ACE inhibitors were the fi rst to actually have an 
impact on the symptoms, but more important on morbidity and mortality. In 
the last ten years the treatment of heart failure has advanced and whole new 
categories of drugs have been developed. Despite these new drugs mortality 
has not diminished dramatically.
1.2 Pathogenesis of Heart Failure
When the heart has diffi culty pumping blood at a rate commensurate with 
the requirements of metabolizing tissues or does so only by elevating the 
fi lling pressure, heart failure develops. At the same time the heart switches 
on a number of adaptive mechanisms for maintaining its pumping function 
(93). Essential among the adaptive systems are the Frank-Starling mechanism, 
activation of the neurohumoral systems and myocardial remodeling. 
Increased preload helps to sustain the cardiac performance: reduced 
cardiac output activates neurohumoral responses, leading to vasoconstriction, 
fl uid retention, and cardiac stimulation (93). These adaptations occur rapidly 
and may be adequate to maintain pumping performance for a short time. 
Myocardial hypertrophy and progressive dilation (remodeling) of the failing 
heart account for abnormal proliferative responses and play an important role 
in long-term adaptation to hemodynamic overload. The structural responses 
play a crucial role in the poor prognosis of HF, which results from changes 
in the shape, size, and molecular composition of both cardiac myocytes and 
other cardiac cells (219).
The development of HF is generally progressive where the initial step 
challenges cardiac performance- either systolic or diastolic function. 
Regardless of the initial stimulus, adaptive, compensatory mechanisms are 
activated in both the heart and the circulatory system. These include activation 
of the neurohumoral pathway, specifi cally the renin-angiotensin-aldosterone 
(RAA) system, and the sympathetic nervous system. This activation leads 
to production of several neurohormones, which have both hemodynamical 
1. HEART FAILURE
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and biological effects on the myocardium and the systemic vascular bed. At 
fi rst these mechanisms are compensatory, protecting the heart by balancing 
cardiac output with demands. As the deleterious activation is prolonged the 
compensatory mechanisms become noxious to the myocardium, leading to 
alteration of the existing structures (93).
The activation of adaptive mechanisms also leads to the development and 
progression of LV dysfunction and ultimately to a clinical syndrome of HF 
(93).
The purpose of these adaptive mechanisms is to sustain cardiac performance 
in spite of the changed hemodynamic conditions.
1.3 Remodeling → Heart Failure
Left ventricular remodeling is a compensatory process in which mechanical, 
neuro- hormonal, and possibly genetic factors contribute to alteration of 
ventricular size, shape, and function (93). It develops over months and years 
and is crucial to hemodynamic adaptation. It is also irreversible and initially 
adaptive, thus fi nally leading to left ventricular hypertrophy (LVH) and clinical 
HF.
Two major components characterize LVH: hypertrophy of the myocytes 
and myocardial fi brosis, mainly located in the interstitium but also in the 
perivascular areas of the myocardium (347;497).
LVH initially compensates for volume or pressure overload by increasing 
either the size of the left ventricle or its capacity to produce force. Finally, LVH 
impairs the diastolic function by increasing the stiffness of the left ventricle, 
working consecutively against the active phase of relaxation and atrial fi lling. 
Later, the stiffness produced by LVH begins to interfere with contraction, 
thereby also affecting the systolic function of the heart.
LVH is associated with ischemia, arrhythmias, and heart failure and 
represents an independent risk factor of cardiovascular mortality (305). 
The transition from compensated hypertrophy to manifested HF involves a 
complex of events at the cellular and molecular level – hypertrophy of cardiac 
myocytes, changes in gene expression with re-expression of fetal programs 
and decreased expression of adult programs, changes in the nature and 
quantity of interstitial matrix, and cellular death by apoptosis and necrosis. 
HF is progressive, though the velocity of its progression varies depending on 
factors ranging from underlying cause to ethnical factors (93;141).
It seems very likely that the key to the progressive nature of LVH and HF 
is the activated signaling peptide systems. Several of these peptides have been 
shown to induce LVH when infused into animals, and their inhibition has 
succeeded in improving the otherwise very poor prognosis of HF patients. 
The most important of these signaling systems include the RA system, the 
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endothelin system, infl ammatory cytokines and the kinin system, as well as 
the adrenergic system (93).
The balance between cardioprotective elements and components that are 
deleterious to the myocardium (cardiotoxic) determines the progression of 
heart failure and its velocity.
1.4 Cardiotoxic Pathways
Cardiotoxic pathways can be defi ned as signaling pathways that have 
deleterious effects on the myocardium and the cardiovascular system. 
Though the presence of these pathways is essential for normal cardiovascular 
physiology, the transition point from protection to toxicity is defi ne.
1.4.1 Renin-Angiotensin System 
The renin-angiotensin system (RAS) plays a prominent role in cardiac 
remodeling during HF development. Activation of the RA system induces 
formation of angiotensin II, which promotes myocyte hypertrophy, fi brosis, 
and chamber dilation in the heart, exerting similar effects to the β-adrenergic 
system. It also promotes water and sodium retention and exerts electrolytic 
disturbances (93).
The RAS involves systemic and local components. Although all the 
components of RAS are present in the heart, not all of them are believed 
to be synthesized there (341;494). The local RAS seems to be activated 
differentially depending on the activating signal and regulated independently 
from the circulating RAS (180;490).
Both local and systemic RA cascades are activated early during the 
progression of HF, and they are considered the major contributor to most 
cardiovascular diseases. In fact, the most important drugs for HF are based on 
blocking the RAS with ACE inhibitors, aldosterone inhibitors, or AT receptor 
inhibitors. Angiotensin converting enzyme (ACE), which converts Ang I into 
Ang II, also degrades bradykinin into its metabolites.
1.4.2 Endothelins
Endothelins are the most powerful vasoconstrictors identifi ed. The effects 
of four different endothelin peptides (ET-1-4) are mediated through two G-
protein-coupled receptors (ETA, ETB) that are distributed throughout tissues, 
notably the vascular endothelium, smooth muscle cells, and cardiomyocytes. 
In HF patients circulating ET-1 is elevated and correlates with the severity 
of hemodynamic disturbances and symptoms (300). Though endothelins are 
known to exert different effects on myocardial contractility in both normal and 
1. HEART FAILURE
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failing hearts (272;442), vasoconstriction is the most apparent. However, the 
endothelin system is not as important as the adrenergic system and RAS for 
regulation of myocardial performance (312).
1.4.3 Cytokines 
There is convincing evidence suggesting that infl ammation plays a signifi cant 
role in the pathogenesis of heart failure. Cytokines are highly potent 
endogenous peptides produced by a variety of cell types and act as essential 
mediators and modulators of many biological systems. Tumor necrosis 
factor (TNF)-α, interleukin (IL)-1α, IL-1β, and IL-6 have been classifi ed as 
proinfl ammatory cytokines that play important roles in primary host responses 
and tissue repair. In experimental models, infl ammatory cytokines promote 
left ventricular remodeling and acute reversible contractile dysfunction 
(299;429). In patients with chronic heart failure, increased plasma levels of 
proinfl ammatory cytokines, including TNF-α and IL-6, correlate with both the 
severity of disease symptoms and clinical outcome (256;456).
The cytokines act in concert with certain cytokine inhibitors and soluble 
cytokine receptors to regulate the human immune response. Cytokines such 
as TNF-α have an immediate negative inotrophic effect on the myocardium. 
Some of them are partly responsible for the increased oxygen consumption 
related to the impaired economy of contraction (189). Some interferons (IFN-
γ, IFN-α) also depress the contractility of the myocardium and are involved in 
the progression of LVH and HF (88;422).
1.4.4 Adrenergic System
One of the most powerful deleterious systems is the symphatic or adrenergic 
system. The effects of adrenergic system include activation of α- and 
β-adrenergic receptors, which are targets of endogenous adrenaline or 
noradrenaline as well as exogenously-administered β-blockers (243). In 
chronic HF, increased adrenergic signaling is present and in continuous 
stimulation, a down-regulation especially of the β-1 adrenergic receptors is 
present (58). Desensitization of these receptors together with the reduced 
number of receptors, seen in HF, can be seen as a protective mechanism in the 
failing myocardium (58).
The adrenergic pathway is activated early in the course of HF and at fi rst 
serves to compensate for the functional impairment of the myocardium, 
but ultimately results in deterioration of cardiac function, altered structure, 
and heart failure. Activation of the adrenergic system induces peripheral 
vasoconstriction, which in turn increases after-load and oxygen consumption. 
It causes hypoperfusion and increased anaerobic metabolism in tissues. 
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Excess noradrenaline increases intracellular calcium, which is directly 
lethal to cardiomyocytes. Sympathetic activation with excess noradrenalin 
stimulation promotes eccentric myocyte hypertrophy, enhances apoptosis 
of cardiomyocytes, and produces detrimental changes in contractile and 
metabolic proteins via alterations of gene expression in cardiomyocytes 
(90;135). Activation of the sympathetic system also promotes fi brosis and 
activates numerous other signaling systems such as the renin-angiotensin 
(RA) system.
1.5 Cardioprotective Pathways
When cardiotoxic pathways are activated in the myocardium, also opposing 
systems that protect the myocardium from deleterious signals are activated. 
To these protecting systems include, for example, the kinin, natriuretic, 
and adrenomedullin systems as well as the newly discovered urocortin and 
adiponectin systems. The kinin system is the main focus of this review and it 
will be closely examined later.
1.5.1 Natriuretic Pathway
In the late 1970s it was discovered that infusing atrial extracts into hypertensive 
rats lowered blood pressure and resulted in natriuresis (101). The peptide was 
later isolated and named atrial natriuretic peptide (ANP). Natriuretic peptides 
are a peptide family constituting ANP, brain natriuretic peptide (BNP), and 
C-type natriuretic peptide (CNP). ANP and BNP are mostly synthesized in the 
myocardium and secreted in response to muscle stress. CNP is considered a 
neurotransmitter in the central nervous system, but is also widely distributed 
throughout the vasculature and is found in high concentrations in the 
endothelium where it plays a role in the regulation of local vascular tone 
(495;506). ANP and BNP are widely used as indicators of myocardial ischemia 
and heart failure, where they can be used as prognostic biomarkers (320). The 
effects of natriuretic peptides are mediated through three receptors, namely 
NPR-A, NPR-B, and NPR-C. ANP and BNP bind preferentially to NPR-A and 
CNP prefers NPR-B. All three peptides bind to NPR-C, which seems to clear 
the natriuretic peptides from the circulation.
The peptides induce diuresis and natriuresis and also regulate blood pressure 
mainly via vasodilation by inhibiting the synthesis and secretion of aldosterone 
and renin. They inhibit vascular SMC proliferation and hypertrophy of cardiac 
myocytes and regulate systemic vascular permeability (203). Peptides act as 
circulating hormones, but also as autocrine and paracrine factors. In heart 
failure, the levels of ANP and BNP in plasma are increased and they are 
considered to compensate for heart failure (267).
1. HEART FAILURE
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1.5.2 Adrenomedullin
Adrenomedullin is a potent vasodilating peptide that was originally isolated 
from pheochromocytoma tissue (227). It is secreted by many cardiovascular 
tissues and cells including the myocardium, vascular endothelium and vascular 
smooth muscle cells (191). Adrenomedullin has similar effects as natriuretic 
peptides thus, it promotes vasodilation, natriuresis, diuresis, angiogenesis, 
antifi brotic effects, and anti-oxidative actions (227;324). Plasma adrenomedullin 
levels are increased in patients with various cardiovascular diseases, including 
hypertension, heart failure, and renal failure. Adrenomedullin has also showed 
to have an impact on the cardiac contractility and depending on the down-
stream signaling cascades, it either decreases or increases the contractility of 
cardiomyocytes (57;253;430). Adrenomedullin as well as natriuretic peptides 
are mainly degraded in the human heart by neural endopeptidase (NEP).
1.5.3. Erythropoietin (EPO)
In response to ischemia, the cells upregulate erythropoietin through increased 
expression of hypoxia-inducible factor 1 α (HIF-1 α). Patients, suffering from 
chronic heart failure, are often anemic and recombinant-erythropoietin (EPO) 
has been successfully used in the treatment of HF patients (414).
Increased Hb in HF patients improves cardiac function, but EPO seems to 
exert also some non-hematopoietic effects. Erythropoietin has shown to have 
anti-apoptotic and antioxidative effects as well as angiogenesis promoting 
effects (373;418). 
Recent studies showed that EPO treatment reduced the infarct size (both 
brain and heart infarction) in ischemia/reperfusion experiments. In vivo and 
in vitro studies reported reduced apoptosis in myocardial cells and normalized 
hemodynamic functions after reperfusion in rodents. Although the mechanisms 
of EPO in preserving cardiac functions are mainly unknown, the anti-apoptotic 
role of EPO has been speculated (69;463).
1.5.4 Other Cardioprotective Proteins
Urocortins (UCN) represent a recently discovered family of cardiac peptides. 
The name applies to three peptides (urocortin I-III) belonging to the 
corticotrophin-releasing-factor (CRF) super family. Three urocortins have so 
far been identifi ed, and they exert their effects through two G-protein coupled 
receptors (269). Urocortin-I has shown to have potent coronary vasodilator 
and cardiac inotrophic effects. The effects resemble the effects of natriuretic 
peptides, and in animal models Urocortin I stimulates ANP and BNP secretion 
from cardiomyocytes (113).
Adiponectin is a protein secreted by adipocytes that has also been 
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connected to cardioprotective systems (340). It exhibits favorable effects on 
atherogenesis, endothelial function, and vascular remodeling by modulating 
the signaling cascades in vascular cells. Recent fi ndings have shown that it 
can directly affect the signaling of cardiac cells and is benefi cial in cardiac 
remodeling and also in acute cardiac injuries such as myocardial infarction 
(190).
Cardiotrophin-1 (CT-1) is a cytokine, also shown to have cardioprotective 
effects. The plasma level of CT-1 is increased in HF and it seems to have 
diagnostic and prognostic value in heart failure. The level of CT-1 is increased 
in hypertension, valvular diseases, hypoxia, and myocardial infarction and 
it stimulates cardiomyocyte proliferation. CT-1 has also shown to exert 
protective effects against ischemia/reperfusion injury, infused both prior to 
ischemia and at reperfusion. The results suggest that CT-1 has a protective 
role in myocardial diseases and it may play a role in decreasing myocardial 
damage (66;258). 
On the basis of these fi ndings, it has been hypothesized that a balance exists 
between harmful signaling systems and cardioprotective systems, which 
stabilizes the homeostasis of the normal heart. This equilibrium is disturbed 
in the beginning of the pathogenesis of HF, resulting in the onset of LVH, 
accompanied by remodeling and followed by impaired function of the heart, 
fi nally leading to heart failure. 
2. The Kininogen-Kallikrein-Kinin Pathway
2.1 History
Kininogens are defi ned as circulating proteins that contain BK or lys-BK. These 
peptides and their active metabolites assume particular importance as natural 
ligands of two BK receptors (BK-1R and BK-2R). Interest in the kinin system 
originates from experiments done a hundred years ago by two surgeons who 
observed that an alcohol-insoluble fraction of human urine caused hypotension 
when injected into dogs (480). In 1937 Dr Werle discovered that kallikrein is 
a proteolytic enzyme that liberates the active polypeptide, kallidin, from the 
plasma protein kininogen (480). He also noticed the degradation of kinins and 
identifi ed them as peptides (481).
In the late 1940s Rocha e Silva discovered that trypsin, when incubated 
with blood, released a substance that contracted the ileum of a guinea pig, 
and the substance was named bradykinin. He later succeeded in purifying the 
substance and determined that it was a peptide (378).
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2.2 Kininogens
Kininogens are mainly synthesized by hepatocytes, and after posttranslational 
modifi cations they are secreted into the circulation (433). Two forms of 
kininogens have been identifi ed in humans, namely high-molecular-weight 
kininogen (HMWK) and low-molecular-weight kininogen (LMWK), 
which differ in size, structure, and function. Their common basic structure 
– an aminoterminal heavy chain – is linked to varying carboxyterminal light 
chains, allowing the distinction between low- and high- molecular-weight 
kininogens (42).
BK and kallidin are formed from either HMWK or LMWK, respectively, 
by means of the enzymatic action of kallikreins. Several studies have shown 
that, at least, endothelial cells, platelets and granulocytes have binding sites 
for HMWK (168;399;465).
The binding of kininogens requires the presence of Zn²+ cations, suggesting 
it is necessary for the expression of the kininogen receptor (510). The affi nity 
of LMWK and HMWK for binding is similar, but the number of binding sites 
for kininogens varies greatly between cells. Thus, platelets have approximately 
1000 binding sites/cell and endothelial cells have between one and ten million 
binding sites/cell (92). When HMWK is bound to an endothelial cell it 
activates prekallikrein to release kallikrein, which in turn cleaves BK from 
HMWK (318). 
The kininogen system is involved in infl ammation and blood coagulation. 
In tissue destruction or thrombus formation the contact activation and 
coagulation activation occur in vivo, but the physiological function of the 
kallikrein system in coagulation has been challenged.
Fig 1. The human kininogen-kallikrein-kinin -system.
2.3 Kallikreins
Kallikreins are serine proteases found in glandular cells, neutrophils, and 
biological fl uids. Kallikreins are divided into two groups: plasma and tissue 
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kallikreins, which differ in their molecular weight, pI (isoelectric point), 
substrate specifi city, immunological characteristics, type of kinin released, 
and functional importance. Kallikreins release vasoactive kinin peptides 
through enzymatic action (321). Enzymes that possess the capacity to release 
kinins from kininogens are collectively called kininogenases, which include 
enzymes such as kallikreins, trypsin, neutrophil elastase, and plasmin (236).
Plasma prekallikrein (PPK) is synthesized and secreted by hepatocytes, 
forms a complex with HMWK, and circulates in the plasma attached to the 
external surface membrane of neutrophils (182). When the Hageman factor is 
activated, either by interaction with neutrophil or endothelial membranes or 
by binding to negatively charged surfaces, it enzymatically converts plasma 
prekallikrein to plasma kallikrein. A feedback mechanism causes further and 
rapid activation of the Hageman factor and together with cyclic conversion of 
PPK to kallikrein, results in local formation of kinins from kallikreins (37).
The major function of plasma kallikrein is to release BK from HMWK by 
hydrolysis of Lys-Arg and Arg-Ser bonds (217). It also participates in surface-
dependent activation of blood clotting, fi brinolysis, regulation of vascular 
tone, and infl ammation. Molecular events in blood clotting involve a number 
of proenzymes, namely plasma prekallikrein, factor XII (Hageman factor), 
factor XI, and HMWK, of which HMWK is essential for the coagulation 
cascade (217). Although LMWK is a poor substrate for plasma kallikrein, it 
can form BK in the presence of neutrophil elastase (387).
Tissue kallikrein (TK) is a single-chain acidic glycoprotein that differs 
completely from plasma kallikrein (37). Tissue kallikrein has strong kininase 
activity, and it is locally synthesized and releases mainly kallidin from both 
kininogens, though the main substrate is considered to be LMWK (184;273). 
Tissue kallikrein can also cleave other precursors to release active peptides 
(37). Tissue kallikrein has been isolated from various tissues, including 
the heart and arteries (34;302). Unlike with plasma kallikrein, continuous 
synthesis and secretion of kallikrein can occur in synthesizing tissues, 
producing kallidin from local and plasma-derived LMWK. This also means 
that as tissue kallikrein produces kinins continuously, it has an important role 
in the endothelial function in arteries. It also participates in blood pressure 
regulation and cardioprotection in early and late ischemic preconditioning 
(357).
Kallikreins can also activate BK-2Rs independently of kinin generation. 
This introduces a “shunt” concept into the kallikrein-kinin system in which 
the normal multistep-cascade to release bradykinin is effectively bypassed as 
kallikrein directly activates BK-2 receptors (39).
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2.4 Bradykinin and Kallidin
Kallidin Lys1-Arg2-Pro3-Pro4-Gly5-Phe6-Ser7-Pro8-Phe9-Arg10
Bradykinin Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9
Fig 2. The structure of kinins 
The two peptides usually referred to as kinins are bradykinin (BK) and kallidin 
(lys-BK). Their amino acid sequences are shown in Fig 2. 
In human heart kallidin is rapidly cleaved into BK, and BK is rapidly 
metabolized into BK-(1-8), BK-(1-7), and BK-(1-5), shown in Fig 3 (234).
Of the kinin metabolites, des-Arg9-BK and des-Arg10-KD can activate BK-
1 receptors, and BK-2 receptors can be activated by both BK and KD. Of the 
bradykinin degradation products, BK-(1-7) is considered to be inactive and 
BK-(1-5) to be active in the coagulation cascade (177).
Fig 3. Kinins, their degradation products, and the degrading enzymes in human heart
In 1960 the fi rst amino acid sequence proposed as bradykinin lacked a 
single proline residue in position 7; the correct sequence was established later 
that year (50).
The half-life of kinins is very short and they are rapidly degraded into 
inactive metabolites. In plasma the half-lives of BK and KD are estimated 
to be < 30 s (144;294). The concentration of BK in the circulation and 
tissues is very small, and the concentration of kallidin is even smaller (50). 
The concentrations (25-50 pM) of kinins in tissues are higher than in the 
circulation, refl ecting the fact that tissues produce kinins and also that BK 
does not participate in systemic blood pressure regulation (314). Bradykinin 
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can be found in all secretions of the body, i.e. urine, saliva, sweat, and lacrimal 
fl uid, as well as in tissues such as the heart, vasculature, blood, kidney, gastro-
intestine track, lungs, skin, brain, and nervous system (72;302;403).
The most important hemodynamic effect of bradykinin is vasodilation, 
and vascular endothelial cells in the heart are the primary source of BK. 
Endogenous BK participates in the regulation of coronary vascular tone 
through BK-2Rs, thus vasodilation can be abolished by a BK-2R antagonist 
Icatibant. Exogenously-administered BK is also a potent coronary artery 
vasodilator (84;172;195;348). Vasodilation is partly achieved by stimulating 
vascular endothelial cells to produce NO but also by activating ECs to produce 
prostacyclin (PGI
2
). The endothelium- derived hyperpolarizing factor (EDHF) 
is produced by activating BK-2Rs (172;226).
BK-induced vasodilation increases local hyperemia and reduces blood 
pressure, thus reducing systemic and local vascular resistance (172;397). It 
also stimulates nociceptive afferent nerves, promotes formation of edema 
by increasing vascular permeability, and participates in coagulation and 
fi brinolysis. BK induces antiproliferative effects via BK-2Rs by inhibiting 
several growth factors that inhibit the hypertrophy of myocytes, thus indicating 
that an intact kinin system is essential for the regulation of the myocardium 
(207;293;381).
Kallidin can be detected in the heart and circulation as well as in urine and 
the kidneys (127). Kallidin concentrations are lower than BK in both plasma 
(< 1 pM) and tissues (0.5- 4.0 pM), suggesting that the formed kallidin is 
rapidly degraded into BK (70).
Kinin concentrations are regulated by their formation, but especially by their 
degradation. There are many enzymes responsible for degradation of kinins, 
which differ from tissue to tissue, thus kinin profi les vary greatly between 
tissues. Also both BK-1 and BK-2 receptors, their secondary messenger 
pathways, and their responses to ligands differ, depending on the cell type 
and tissue observed. So, the same stimulation can cause entirely different 
activation in another tissue with the same ligand.
2.5 Kinin-degrading Enzymes
 APM APP NEP CPN
 ↓ ↓ ↓ ↓
Bradykinin (Lys0-) Arg1- Pro2- Pro3- Gly4- Phe5- Ser6- Pro7- Phe8- Arg9
 ↑ ↑ ↑
 ACE ACE CPM
Fig 4. Sites and enzymes which degrade BK
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Kinin-degrading enzymes are collectively called kininases. There are four 
major kininases that cleave kinins from the carboxyterminal end. There 
are also enzymes that cleave kinins from the aminoterminal end, but their 
signifi cance seems to be less important – at least in the heart.
In humans, plasma BK is mainly metabolized by three metallopeptidases 
– ACE, APP, and CPN (41;99). In addition to ACE 1 a homologue of ACE 1 
-ACE2-has recently been presented. In this review, ACE refers to ACE 1.
2.5.1 Aminoterminal-end-cleaving Enzymes
Aminopeptidase M (APM) is an enzyme detected in vascular endothelial and 
epithelial cells in the intestine and renal tubules, and it degrades kallidin into 
BK (Fig 4) (233;337;488). The concentration of kallidin in the human heart is 
very low, and kallidin is rapidly degraded into BK through the action of APM, 
likely by fi broblasts (233).
Aminopeptidase P (APP) is a membrane-bound enzyme located in 
endothelial cells, and particularly high activities have been located in the 
kidney, heart, and spleen. APP cleaves the fi rst amino acid of BK, converting 
it into inactive BK-(2-9) (81).
In rats, APP together with ACE are the predominant kininases that participate 
equally in kinin degradation (108;137). A recent study with rats showed that 
inhibition of APP potentiated the cardioprotective actions of kinins (489). The 
importance of APP in humans emerges in the presence of ACE inhibition, 
when APP represents the main inactivating pathway of BK (99). 
2.5.2 Carboxyterminal-end-cleaving Enzymes
The four major enzymes responsible for cleaving kinins from the carboxyterminal 
end are: angiotensin-converting enzyme 1 (ACE), carboxypeptidase’s N and 
M (CPN, CPM), and neutral endopeptidase (NEP). Based on their enzymatic 
action, kininases are divided into kininase I and II. To the fi rst belong CPN 
and CPM and to the latter, ACE and NEP. Kininase I cleaves carboxyterminal 
Arg-9 and kininase II cleaves terminal dipeptide Phe8-Arg9 of kinins. Fig 4 
shows the main cleavage sites of BK.
ACE is mainly localized in the pulmonary vasculature, where it destroys 
more than 99% of the circulating BK in a single passage through the pulmonary 
circulation (367). It has generally been thought to be the most important BK-
degrading enzyme in the heart and plasma (108;125). Accumulating evidence 
suggest that in human myocytes, BK is degraded mostly by NEP into inactive 
BK-(1-7), and only about 10% is degraded by ACE (126;233;354). The activity 
of kinins seems to be constant in humans in spite of cardiovascular diseases 
(233). In animals there is some evidence that the level of degrading enzymes 
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differs in diseased hearts (367). The degradation of kinins in the human heart 
is due to ACE, NEP, and APM, of which ACE is probably the most important 
in the endothelium, NEP in the myocardium, and APM in fi broblasts.
Kinins are degraded in plasma mainly by ACE, which cleaves bradykinin 
into inactive BK-(1-7) and into BK-(1-5), which accompanies the coagulation 
process. 
3. Kinin Receptors
Fig 5. Schematic diagram of a G-protein receptor
Two types of 7-transmembrane G-protein-coupled receptors mediate the 
cellular effects of kinins, namely BK-1R and BK-2R. A third G-protein-coupled 
receptor named GPR-100 was recently detected and suspected to be a kinin 
receptor (49). Bradykinin binds to GPR-100 acts and it resembles BK-2R with 
a sequence homology of 27%. The receptor has now been confi rmed as an 
insulin-like receptor with relaxin-3 (insulin-like peptide), a ligand (154;265).
The existence of BK receptors was suspected in the early 1970s 
(100;474;479). The fi rst defi nition of the receptor was made in 1974 (29). In 
1977 two different BK receptors were described in rabbit and rat aortas(369). 
Later the existence of the two receptors was confi rmed, one being constitutively 
expressed (BK-2R) and the other being inducible (BK-1R) (369). The fi rst 
fi ndings of BK receptors in the heart were described in the myocardial nerve 
endings of dogs (425), and almost 20 years later in rat cardiomyocytes (307).
These pharmacologically different receptor subtypes are found interspecies, 
which explains some of the discrepancies in previous studies done with various 
animals. 
Kinin receptors have been under investigation now for more than 30 years. 
The scientifi c interest in kinins arouse after the recognition that kinins induce 
contraction of smooth muscle cells in many vessels, but at the same time 
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stimulate the production of endothelial vasodilators, thus inducing vasodilation 
and relating kinins to cardiovascular diseases (85;445). The known positive 
cardiovascular effects are mainly mediated via BK-2Rs. Substantially less 
information exists about the functionality and signifi cance of BK-1Rs. 
3.1 BK-2 Receptors
3.1.1 History
BK-2Rs were fi rst discovered in cat interstitium, rat stomach and uterus, and 
rabbit aorta and jugular vein by a in 1975 (28;29;369). The receptor encoding 
for 366 amino acid residues was cloned from rat uterus SMCs in 1991 (295).
Subsequently, the human receptor was cloned from a fi broblast cell 
line by PCR and cDNA library screening (183), and the human gene was 
encoded (128;215). The gene consists of three exons and two introns located 
in chromosome 14, specifi cally in 14q32. It codes for a 391 bp amino acid 
protein with a molecular mass of 41 Da, which has about 80% homology with 
mouse and rat BK-2 receptors (215;271;359).
3.1.2 Distribution and signaling of BK-2 Receptors
The “native” kinins – BK and kallidin – generated by plasma or tissue 
kallikreins in all mammalian species have a high affi nity for BK-2Rs. None of 
the fragments of BK retain a signifi cant affi nity for BK-2Rs.
The constitutively expressed BK-2Rs have been identifi ed in most tissues 
and cells: endothelial cells (146), smooth muscle cells (vascular and non-
vascular) (36;38;381), and fi broblasts (183). They have also been detected 
in mesengial cells (13;285), neurons (426), neutrophils (27), and tumor cells, 
such as adenocarcinoma, lymphoma and hepatoma (491).
BK-2R signaling in the vasculature leads to either vasoconstriction or 
vasodilation (85;381) and promotes antithrombotic effects (59;407). Depending 
on the cell type, activation induces proliferative or antiproliferative responses 
in SMCs and fi broblasts, respectively (160).
Kinin receptors undergo multiple post-translational modifi cations, including 
glycosylations and disulfi de bridge (cystine) formation, in their extracellular 
domains. Most of these modifi cations, including phosphorylation, occur in 
a ligand-independent manner, although phosphorylation and possibly also 
acetylation appears to be regulated primarily through receptor activation 
(355;424).
Of the post-translational modifi cations in BK-2Rs, glycosylation does 
not appear to affect ligand-receptor interactions (502). BK-2Rs contain two 
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cysteine residues in the tail region, which can be modifi ed by palmitoylation, 
which further modifi es receptor coupling, internalization, resensitization, and 
intracellular traffi cking (355;424). Agonist -induced reversible phosphorylation 
plays an important role in the desensitization of GPCRs, which may also affect 
endocytosis, recycling, traffi cking, and coupling of the receptors.
BK-2 receptors are phosphorylated upon stimulation, leading to receptor 
desensitization (147;210). Repeated or continuous stimulation leads to 
internalization of the desensitized receptors. Upon stimulation the receptors 
are redistributed into plasmalemmal caveolae, and the receptor-caveolae-
containing vesicles are thereafter endocytosed and taken into cells. The 
receptors are recycled back to plasma membranes after a refracting period 
(43;46)
3.1.3 Physiological Eff ects of BK-2Rs
In animals and humans the vasodilation under normal conditions is mediated 
by BK-2Rs (43;46) and thus BK-2Rs mediate hypotensive effects. In the heart, 
BK-2Rs appear to be antiarrythmic (262), reduce infarct size, and contribute 
to preconditioning of the heart against ischemia (61;89;166;504)
BK-2Rs also have an impact on angiogenesis. In animal models receptor 
activation leads to angiogenesis via several downstream signaling pathways, 
notably activating eNOS, COX-2, ACE, and VEGF (133;310;415;443).
In the kidneys, BK-2Rs are expressed in all nephron segments, and receptor 
activation increases renal blood fl ow, and induces diuresis and natriuresis 
with no change in the glomerular fi ltration rate (205;279). Animal studies 
have shown that BK-2R activation in nephrons promotes antifi brotic effects 
(389;395). BK-2R activation prevented tubulo-intestinal fi brosis but not 
perivascular or glomerular fi brosis in hypertensive rats (185). In hypertension 
it has been shown that the local kinin system plays a signifi cant role in renal 
protection (11;503). The protective effect is augmented with ACE inhibitors 
and vasopeptidase (dual ACE+NEP) inhibitors (405). Some confl icting results 
on BK-2R renoprotection have been published with BK-2R knock-out mice 
(392).
BK-2Rs affect glucose metabolism by stimulating glucose uptake in 
the presence of insulin (206;411), and hyperglycemia upregulates BK-2Rs 
in SMCs (86). The role of BK-2Rs in the development of type-1 diabetic 
nephropathy has been suggested but is controversial (208). Icatibant reduced 
glomerular hyper fi ltration, a phenomenon that is typical in the early phase of 
diabetes, but another study didn’t fi nd any differences in the progression of 
diabetic nephropathy in BK-2R -antagonized rats (12;453).
Studies of diabetic rats show activation of BK-2Rs and contribution 
to diabetic nephropathy, where activation of the connective tissue factor, 
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collagen I, and the transforming growth factor-β (TGF-β) are involved (435). 
The results have been confi rmed in BK-2R -/- diabetic mice in which the 
renoprotective effect was associated with increased renal expression of BK-
1Rs and AT-2Rs (435;436).
In the gastro-intestinal tract, BK and BK-2Rs induce SMCs to either relax 
or contract (17;145). The same phenomenon is also seen in smooth muscle 
cells in the uterus, bladder, and bronchi (209;450). The activation of BK-2 
receptors has also been linked to infl ammation and pain (116;117).
In the respiratory tract, kinins induce broncoconstriction, and BK and BK-
2Rs are associated with the pathogenesis of asthma (116;117).
A potentially important role of BK-2Rs in asthma was demonstrated by a 
clinical trial in patients where icatibant dose-dependently increased pulmonary 
function test values. The effect was considered anti-infl ammatory rather than 
bronchodilatory (9).
3.1.4 Induction of BK-2 Receptors 
The stimulation of BK-2Rs does not infl uence the formation of kinins, 
implicating that there is no feed-back regulation between kinins and BK-2Rs 
(71;281).
The native ligand of BK-2Rs is bradykinin, but the receptors can also be 
stimulated by kallidin, kallikreins, or cathepsin G and trypsin (39;179).
Substantially divergent binding affi nities have been reported for BK-
2Rs in various tissues and preparations. The receptor affi nity also depends 
on receptor coupling, and the phosporylation state and extent of receptor 
occupation (43;251;377). 
3.1.4.1 Infl ammation 
Infl ammatory cytokines can up-regulate BK-2Rs. In a T24 transitional 
carcinoma cell line, interferon-γ (IFN -γ) stimulated BK-2R expression (270). 
Interleukin 1-β (IL1-β) and the tumor necrosis factor-α (TNF-α) induce BK-
2Rs through a post-transcriptional mechanism by activating PKA and p38 
MAP kinase pathways (173;270;401).
In human airway smooth muscle cells, BK induces the release of IL1-β 
via cAMP, IL- 8, prostaglandin E2 (PGE
2
), COX-2, and IL-6 by a BK-2R 
dependent pathway (327;344;507). As BK is considered proinfl ammatory in 
lungs, BK-2 receptors are possibly involved in the pathogenesis of asthma 
(30;78).
It has been suggested that BK-2Rs play a role in acute infl ammatory response 
in contrast to BK-1Rs, which account for chronic infl ammation (327).
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3.1.4.2 ACE
Fig. 6 The renin-angiotensin system. For abbreviations see the text below.
The renin -angiotensin system is a complex system that regulates the 
cardiovascular physiological processes. The primary effector molecule 
of this system is the potent vasopressor angiotensin II (Ang II), which has 
both benefi cial and deleterious effects. Angiotensin-converting enzyme 
(ACE) is an ectoenzyme that generates Ang II by catalyzing its conversion 
from Ang I. In addition, ACE hydrolyses both bradykinin and kallidin (498). 
ACE preferentially hydrolyses bradykinin rather than Ang I and is especially 
abundant in the endothelial cells of lung vessels, but is also expressed in other 
endothelial cells, some smooth muscle cells, and monocytes (75). After a 
single passage through the pulmonary circulation, ACE degraded over 95% of 
administered BK in humans (51). ACE is heterogeneously distributed in the 
vascular tree, which may be of importance to regional blood fl ow (282). 
ACE inhibitors exert benefi cial effects on vascular endothelial function 
and vascular remodeling, many of which many are considered to be BK-2R-
mediated effects (278;396). The benefi cial effects are generally attributed to a 
decrease in Ang II and an accumulation of BK (278;483). ACE is also able to 
hydrolyse Ang II into Ang (1-7), which potentiates the vasodilating effects of 
BK, by inhibiting degradation but also by resensitizing BK-2Rs (142;446).
Ang (1-7) is a vasodilating peptide that counteracts the effects of Ang II. 
It acts by binding to a receptor of its own,- an orphan receptor,-Mas-,or to an 
AT-1 or AT-2 receptor, and participates in the regulation of cardiac function, 
coronary perfusion, and endothelial function (268;386). The vasoconstricting 
effects, described with high Ang (1-7) concentrations, are likely due to 
stimulation of AT-1R (358;446;459). Ang (1-7) is also formed by degradation 
of Ang I or II by a novel enzyme, -ACE-2 (115;471).
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ACE-2 is a newly discovered enzyme that under normal conditions is 
located in the myocardium or vascular endothelium. It hydrolyzes Ang II into 
angiotensin (1-7), angiotensin I into angiotensin (1-9), cleaves kallidin but 
not BK, and is insensitive to ACE inhibitors (471). It has been suggested that 
ACE-2 counteracts the function of ACE. ACE-2 - KO mice have severely 
impaired cardiac function and thinning of the left ventricle wall, but not altered 
blood pressure or increased cardiac fi brosis. HIF-1-α related genes, induced 
by hypoxia (PAI-1 and BNIP3), are up-regulated, suggesting a role for ACE-2 
in cardiac ischemia (96;115). There is also evidence, that ACE-2 is induced in 
the myocardium of heart failure patients (62;511).
Over the last decade there have been a number of reports showing that ACE 
and ACEIs amplify the responses of BK and BK-2Rs. Their cardioprotective 
effects are partly due to the reduction of BK degradation, but clearly there are 
other potentiating effects (193;483). ACEIs not only facilitate the accumulation 
of locally formed BK, they also directly affect BK-2R signaling, resulting in 
an enhanced response to BK. They stabilize BK-2Rs in a high affi nity state, 
thereby preventing and/or reversing BK-induced sequestration to caveolae 
before internalization (33). The BK effects have also been suggested to be 
augmented by ACE-BK-2R cross -talk at the cell membrane (33;309). This 
could result from a steric relationship between the enzyme and the receptor or 
from heterodimer formation (283;308).
Both Ang (1-7) and Ang (1-9) induced reactivation of BK-2Rs in Chinese 
hamster ovary cells (CHO). The effect was attributed to a conformational 
change in the ACE-BK-2 receptor heterodimer (82;283).
All these results refer to a complex RAA-kinin system interaction, and 
despite the numerous studies on this subject, its physiological relevance is 
still not evident. 
3.1.5 Inhibition of BK-2 Receptors 
The fi rst weak, non-receptor-specifi c antagonists of the BK-2Rs were generated 
in 1985 (467). A specifi c and potent antagonist HOE-140 or icatibant was 
introduced in 1991 (188) and is still the most commonly used antagonist, 
despite various chemical subclasses of BK-2R antagonists discovered later 
(14;383).
BK-2R inhibitors have been developed for clinical use and icatibant is 
currently used as a drug for treating angioedema. Unfortunately the results 
have not been as promising as hoped (31;175). 
Stimulation of BK-2Rs with agonists reduces the affi nity of the receptor 
towards ligands, thereby requiring higher ligand concentrations for stimulation 
(107). Long- term (> 24 h) stimulation of BK-2Rs reduces the surface binding 
sites by means of a post-translational mechanism that reduces receptor protein 
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synthesis and increase receptor instability (45).
The activation of BK-2Rs involves phosphorylation and desensitization of 
the receptor and subsequent internalization where the quantity of receptors 
decreases, which is also observed as the aminoterminal end of the receptor 
dimer (43;102). Depending on the ligand, recycling of the receptor can take a 
long time or it can be shortly restored to the plasma membrane. Internalization 
of BK-2Rs seems to be short-lived, since upon withdrawal of the agonists, 
a complete restoration of the receptor follows in 30 minutes (486). It also 
appears that BK-2Rs are almost completely recycled and therefore do not 
involve permanent down-regulation of the receptors (25).
BK-2R down-regulation is observed in some intense and chronic 
infl ammatory states, but the mechanism is unknown (197). Nitric oxide can 





via a cGMP-dependent pathway (311).
3.1.6 Polymorphisms
Several polymorphisms of the BK-2R gene have been described. Point 
mutations occur in both the promoter region and the exons (56). Rieder’s 
group recently sequenced 24 African-American and 23 Caucasian subjects 
and identifi ed 77 SNPs of BK-2Rs. Twenty-fi ve of them have a frequency 
greater than 10% and most of the discovered SNPs were located in the intron 
region. Two relatively highly frequent SNPs, with frequencies of 37%and 
40%, were located at 102bp upstream and 277 bp downstream of exon 2. It 
has not yet been determined if these SNPs alter the function of the BK-2R 
gene and underlying physiological responses (374).
At least three single-nucleoside polymorphisms (SNP) of the BK-2R gene 
are known to have an impact on cardiovascular diseases. First, the promoter 
region -58T/C BK-2R polymorphism has been linked to hypertension in 
African-American, Chinese and Japanese populations. The C allele is an 
independent risk factor of essential hypertension (158;478). Fu et al. showed 
that the polymorphism is related to the development of LVH in hypertensive 
Japanese, but it didn’t correlate with hypertension (155). Also the susceptibility 
to developing a cough with ACE inhibitors is associated with the -58T/C 
polymorphism (319). It is not clear if the T/ C transition causes an altered 
expression at the level of BK-2Rs.
Second, a point mutation at +181 C/T in exon 2 determines the Arg -> Cys 
substitution in the extracellular N-terminal domain. The potency of BK (EC
50
) 
on BK-2Rs is selectively higher in the presence of the T allele. Furthermore, 
the T allele has been proposed to be protective during the development of 
renal failure (196).
And third, the deletion of 9 base pairs (-9/-9) in exon 1 seems to be the most 
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important polymorphism of the BK-2R gene. A lack of this deletion (+9/+9) 
is connected to a lower BK-2 receptor expression and is strongly associated 
with LVH growth response in normotensive men undergoing physical training 
(196). It also relates to impaired LV mass reduction during antihypertensive 
treatment (155;174).
3.1.7 Second Messengers of BK-2 Receptors
Fig 7. The intracellular signaling cascades of BK-2Rs 
(For abbreviations see the text below)
BK receptors are seven trans-membrane G-protein-coupled receptors GPCR 
that, when activated transduce the provided information into intracellular 
second messengers. This process involves the coupling of activated GPCRs 
to various effector systems via their interaction with heterotrimeric G-
proteins. Upon binding, the responses of the intracellular and also the 
intercellular mechanisms vary according to cell and tissue types as well 
as activators. The receptors form homo- and heterodimers and oligomers, 
which also modify their imminent responses. Another modifying factor is 
the initial stimulus, which can activate several different secondary pathways. 







, PLD, and/or PLC (257). The activation of 
the phospholipases induces the formation of inositol triphosphate (IP
3
) and 
diacylglyserol (DAG). Upon stimulation, PLA
2
 activates arachidonic acid 




) production through COX-1 
and COX-2 enzymes (160;496). The phospholipases induce an increase in 
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cytosolic Ca2+ and together with IP
3 
and DAG they activate the protein kinase 
(PKC) pathway (43). The PKC pathway in turn activates various kinase and 
phosphate pathways. The increase of intracellular Ca2+ also activates eNOS 
to synthesize NO (63). eNOS is located in the plasma membrane near BK-2R 
and caveolin-1 complex. By BK-2R activation, eNOS dephosphorylates and 
initiates NO production (165;469).
The G-protein Gαi
2





displayed a two-fold increase in resting cAMP levels, which 
seems to be a BK-2R up-regulating factor, at least in fi broblasts (291).
In endothelial cells, BK-2Rs are located near the plasmalemmal caveolae 
(102). Caveolae are cholesterol- and glycosphingolipid-enriched invaginations 
of plasma membrane that function to bind, organize, and conserve a variety 
of signaling molecules (264). Several signaling proteins, including eNOS, 
interact with caveolin, an oligomeric integral membrane protein that appears 
to serve as the structural “scaffold” within caveolae (16).
When a ligand activates BK-2Rs, they normally transfer into the caveolae 
(102;211). The activated receptors are phosphorylated at Ser/Thr residues, 
located in the C-terminal domains and uncoupled from G-proteins (47;356). 
The receptors are internalized to an intracellular compartment by endocytosis 
and relocated in vesicles. By these actions the receptors are desensitized and 
can not respond to ligands. After internalization, dephosphorylated BK-2Rs 
can be resensitized and recycled back in to the plasma membrane (43). The 
cycle from receptor activation to resensitization and the capacity to bind a new 
ligand takes minutes, thus being a regulative element in BK-2R activation. The 
complex regulation of receptor sequestration and desensitization contributes 
to the differential use of the phosphorylation sites in BK-2Rs (46;356)
G-protein-coupled receptors (GPCRs) constitute a large family of proteins 
that converts external stimuli into intracellular activity. The receptors share 
a common deduced structure, and through their intracellular domains, they 
interact with heterotrimeric G-proteins. The activation of GPCRs initiates 
intracellular second messenger cascades, which ultimately evoke carefully 
controlled cellular responses (326).
The structures and functions of GPCRs are complex, and the secondary 
pathways vary from the cell to the participating ligand. Activation of BK-2Rs 
can induce vasodilatory effects on vessels via three different mechanisms. First, 
they can activate eNOS to produce NO, second they can activate PLA
2,
 which 
promotes synthesis of prostacyclin. A third important vasodilating agent, the 
endothelial-derived hyperpolarizing factor (EDHF), is also related to BK-2Rs. 
The identity of EDHF is unknown, though a metabolite of arachidonic acid, 
epoxyeicosatrienoic acid (EET), is a strong candidate. EETs are synthesized 
the in vascular endothelium, they open calcium-activated potassium channels, 
and they hyperpolarize the membrane of vascular smooth muscle, conducing 
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relaxation (148). It has been proposed that EDHF consists of numerous 
endothelium-derived factors, including NO and PGI
2
, but also reactive oxygen 
species, carbon monoxide, adenosine, peptides, and various metabolites of 
arachidonic acid, which can hyperpolarize the underlying smooth muscle thus 
initiating relaxation (139).
EDHF plays a signifi cant role in resistant vessels, and it has been 
suggested as an important factor also in the vasodilation of coronary arteries, 
human forearm arteries, and renal arteries. It is thought to have relevance in 
preconditioning of the heart (410), and to contribute to vascular reactions in 
diabetes and other cardiovascular associated diseases (431;484). 
The vasodilating substances NO, PGI
2
, and EDHF partly cover each other, 
thus a lack of NO can be substituted by EDHF or PGI
2 
(198;427). In eNOS 
knockout mice, EDHF completely replaces the lack of vasodilation normally 
produced by NO (427). Again, increased NO production inhibits the formation 
of EDHF, suggesting a physiological role for EDHF (224;363).
3.2 BK-1 Receptors
3.2.1 History
Regoli and co-workers also characterized BK-1Rs in the 1970s. The two G-
protein receptors (BK-1R and BK-2R) were shown to differ in pharmacological 
profi le and expression patterns (28;369;370). The gene was cloned from human 
embryonic lung fi broblast and is also located in chromosome 14, specifi cally 
14q32(24). The receptor cDNA encodes the 353 amino acid protein with a 
molecular mass of approximately 41 kDa (303). The two human BK receptor 
genes are located consecutively in the same chromosome sharing a 36% 
genomic sequence homology. Mouse, rat, and rabbit BK-1Rs display functional 
and structural homology with human receptors, with rabbit receptors showing 
the greatest homology (24).
3.2.2 Distribution and Physiological Eff ects of BK-1 Receptors
In humans, BK-1Rs are weakly expressed under physiological conditions, but 
can be induced under pathological stimuli such as tissue injury or infl ammation 
(67;369). However, constitutive expression of BK-1Rs is detected in the 
vascular compartment of rabbits, dogs, and cats (32;109).
BK-1 receptors can be detected in blood vessels, both veins and arteries, 
in cardiac tissue, kidneys, lungs, the central nervous system, ECs, SMCs and, 
fi broblasts (121;303;328). The distribution of BK-1Rs in vascular ECs and 
SMCs differs according to the size of the vessel: no BK-1Rs can be detected 
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in large veins or in the aorta (364).
Kinins able to induce BK-1Rs are des-Arg9-BK and des-Arg10 -kallidin, 
bradykinin or other BK-2R inductors do not activate BK-1Rs (368).
The signaling of BK-1Rs is usually an endothelium-dependent phenomenon 
and can cause either vasoconstriction or vasodilation, depending on the 
species, the vessel, and its location (120;297). In most vessels the main effect 
is dilation, although in rabbit aorta and mesenteric vein as well as in human 
umbilical artery and vein, activation of BK-1Rs causes vasoconstriction 
(1;163;254;298;369;370).
Vasodilation is normally related to infl ammation and is attributed to 
activation of eNOS and subsequently prolonged release of NO (109;120). 





, like in BK-2Rs (297;416). However, there are also confl icting studies 
where BK-1R-mediating vasorelaxation was not sensitive to cyclo-oxygenase 
inhibition, suggesting that prostaglandin release was not involved (362;385). 
This difference may be related to species and regional variation or to the 
absence of a specifi c prostanoid receptor subtype (297).
In some vessels, vasodilation mediated by the induction of BK-1Rs is 
endothelium-independent, which has been attributed to prostaglandin activity 
(376). BK-1Rs are positively coupled to phospholipase A
2 
and induces 
arachidonic acid release (419). Despite prostaglandin synthesis, functional 
responses depend upon local PG sensitivity. Stimulation of BK-1Rs provokes 
PG synthesis and contraction in rabbit SMCs and bovine ECs, the contraction 





vasodilation in rabbit mesenteric and celiac arteries and rat coronary circulation, 
but fail to relax rabbit aorta, although BK-1R stimulation induces PGI
2
 
secretion (151;297;416) This indicates that not all endothelium-independent 
BK-1R-mediated vasodilatory effects are prostaglandin -mediated, despite the 
fact that prostaglandins are consistently released upon BK-1R stimulation.
The prolonged response of activated BK-1Rs is probably related to the lack 
of desensitization and internalization of the receptors (22;289). Human BK-
1Rs are not phosphorylated to any signifi cant degree in either the absence or 
presence of ligands (44).
Many of the peripheral effects of BK-1R activation are pro-infl ammatory: 
vasodilation, increased blood fl ow, increased plasma protein extravasation, 
and activation of leukocyte-EC interactions and leukocyte accumulation 
(8;296). Due to this, BK-1R studies have mainly focused on the regulation 
and expression of receptors in infl ammation and infections (67;352).
The hypotensive responses mediated by BK-1R activation generally 
occur following infl ammation and they have been extensively revealed 
(21;297;371).
Beyond the cardiovascular effects, BK-1Rs have been connected to diabetes 
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(512), chronic pain, and nociception (153) as well as cancer (365;438).
Although BK-1Rs and BK-2Rs seem to couple to similar signal transduction 
pathways, their signaling patterns differ. Also the impact on the differences in 
expression and regulation needs to be explored further.
3.2.3. Induction of BK-1 Receptors 
Knowledge of the functionality and signaling mechanisms of BK-1Rs is 
incomplete. These receptors are present in tissues in negligible quantities and 
they can be induced by various infl ammatory signals that produce vasoactive 
responses. BK-1R up-regulation occurs under the control of specifi c 
cytokines released in infl ammation or after trauma (297;455). Unlike BK-
2Rs, the stimulation of BK-1Rs does not desensitize receptors, indeed BK-2R 
desensitization can up-regulate BK-1Rs. This fi nding supports the hypothesis 
of an integrated system where BK-2Rs mediate acute infl ammatory effects and 
BK-1Rs mediate sustained or chronic infl ammatory responses. ACE inhibitors 
can also directly up-regulate BK-1Rs (202).
3.2.3.1 Infl ammation 
Induction of BK-1Rs is associated with production of infl ammatory mediators, 
stimulation of infl ammatory cells, and activation of several intracellular 
signaling pathways (351). Studies have shown that infection, with or without 
bacterial lipopolysaccarides (LPS), induces BK-1Rs and the vasodilation seen 
in septic infections is, at least partly, mediated by BK-1Rs (104;352).
LPS induces effects that are mediated through infl ammatory molecules 
such as NFκ-β, IL-1β, TNF-α, and PAF, which in turn promote the BK-1R 
up-regulation (346). LPS up-regulates BK-1R expression in rat coronary 
circulation, also possibly via direct action within the vessel wall (382).
Evidence from human lung fi broblasts suggests that receptor up-regulation 
involves activation of PKC, MAPK, and NF-kβ pathways (391;508). IL-1β 
is the optimal inducer of BK-1Rs in various cell types, and up-regulation 
modulates the receptors at both the transcriptional and post-transcriptional 
levels (391;508).
Activation of BK-1Rs reduces renal plasma fl ow and the glomerular 
fi ltration rate (GFR) in rats. This is attenuated when LPS is introduced 
prior to receptor induction, suggesting that activation of BK-1 receptors 
may participate in the modifi cation of renal hemodynamics in infl ammatory 
states (394). Over-expression of BK-1Rs renders transgenic-mice more 
susceptible to endotoxic shock and also exacerbates induced paw edema. 
The hemodynamic response to intravenously administered BK-1R agonist 
surprisingly increased mean arterial blood pressure in transgenic mice (329). 
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These results support a role for BK-1Rs in the modulation of infl ammatory 
responses and hypertensive responses.
3.2.3.2 Allergy and Pain
Huan et al showed that allergen-stimulated bronchial hyper-reactivity in rats 
increased BK-1R expression, which was negated by blocking the receptor 
(199). Completely opposite results were published a few years later (130). The 
majority of animal studies support a role for BK-1Rs in lung infl ammation, 
although the results have not been confi rmed in human studies (136;372).
There is compelling evidence indicating that BK-1Rs play a key role in 
persistent infl ammatory pain (67). Recent studies suggest a role for BK-1Rs 
also in neuropathic pain, which can be addressed as chronic and is in general 
very resistant to traditional medications. In transgenic mice, expressing 
human BK-1Rs, promising results were demonstrated when treating opioid 
-resistant, neuropathic pain with a highly human-specifi c BK-1R antagonist, 
(NVP-SAA164) (153). Another substance, namely ELN441958, has shown 
promising results in diminishing carrageenan-induced hyperalgesia in rhesus 
monkeys (178). Streptozotocin (STZ) -treated mice show characteristics 
of hyperalgesia, which can be completely blocked by a BK-1R antagonist 
(157).
3.2.3.3 Diabetes
In several animal studies, BK -1R up-regulation has been linked to diabetes 
(73;470). Streptozotocin-treated (STZ) diabetic rats showed long-lasting 
up-regulation of functional BK-1Rs in peripheral tissues, which could be 
negated with insulin treatment (73;94). A BK-1R antagonist (Leu8-des-Arg9-
BK) was able to prevent insulin-dependent diabetes, presumably via an anti-
infl ammatory effect, in STZ -treated mice, but a BK-2R antagonist (Icatibant) 
was not able to do so (513). There are also some data concerning the 
development of diabetes that suggest that during the progression of diabetes, 
BK-1Rs are over-expressed and BK-2Rs are down-regulated (68).
A role for BK-1Rs has been suggested in the development of diabetes-
associated retinopathies and neuropathies. A clear increase in BK-1R-specifi c 
binding sites is associated with an enhancement of des-Arg9 -BK induced 
vasodilation in the retinas of STZ-treated rats (2).
3.2.3.4 Other Inducing Factors
Many studies suggest that ACE inhibitors can also directly activate BK-
1Rs. Opposite results have been reported suggesting that ACE inhibitor-
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induced BK-1R up-regulation might be an indirect effect, resulting from low 
endogenous kinin generation (201).
Increased NO production detected with ACE inhibitor treatment has been 
suggested to relate to direct BK-1R stimulation (201). The induction of BK-
1Rs requires Zn²+ binding, inducing elevated Ca2+ levels and subsequent 
activation of eNOS and NO production, which can be blunted by BK-1R 
antagonist Ca-EDTA (201).
There are some indirect data from human heart failures suggesting that 
some of the vasodilatory effects induced by ACE inhibitor treatment are 
mediated through BK-1Rs (487).
It has been suggested that BK-2Rs and BK1Rs can “cross-talk” thus 
potentiating or preventing each other. Persistent stimulation or prolonged 
desensitization of BK-2Rs results in BK-1 receptor up-regulation, suggesting 
that the receptors can co-operate. BK-2R agonists can also directly activate 
the NFκβ pathway, which in turn can activate BK-1Rs (353;390).
A heterologous BK-1-BK-2 receptor-complex has been presented. Human 
BK receptors were spontaneously heterodimerized and the complex was 
associated with proteolytic degradation of BK-2Rs, suggesting a regulatory 
mechanism that participates in the transduction of a signal from BK-2Rs to 
BK-1Rs (216). This formation of a receptor complex may indicate a cellular 
adaptation of kinin signaling in sustained infl ammation.
3.2.4 Inhibition of BK-1 Receptors
There are very limited data, on the inhibitors that infl uence BK-1R signaling.
Glucocorticoids and protein synthesis inhibitors have been shown to 
suppress the up-regulation of BK-1Rs in the rabbit aorta (103).
The number of BK-1Rs is constantly up-regulated in rats exhibiting low 
glucocorticoid levels, and by providing glucocorticoids the receptor levels are 
dropped back to normal levels (65).
The tumor suppressor factor, p53, can transcriptionally activate or silence 
a number of target genes, and it has been shown to inhibit the BK-1R gene 
(499).
3.2.5 Second Messengers of BK-1 Receptors





through which it mediates stimulation (22). 
The two BK receptors have many similar signaling pathways that involves 
elevation of intracellular Ca2+, arachidonic acid release, eicosanoid production, 
and eNOS activation together with NO production (255;457).
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3.3 Knock-out Models
3.3.1 BK-2 Receptor Models
A BK-2R knockout (KO) mouse was fi rst generated by Borkowski in 1995. The 
mouse failed to respond to BK stimulation, such as smooth muscle contraction 
or afferent nerve stimulation. These mice are phenotypically normal and 
fertile and they have normal or only slightly elevated blood pressure, though 
malignant hypertension occurs with excess dietary salt (10;52). They have 
several alterations contributing to cardiovascular function: enhanced effects 
on Ang II, distorted renal development with abnormal nephrons and decreased 
glomerular capillary surface, and decreased renin and COX-2 expression in 
the kidneys (76;393). 
Emanueli studied the cardiac phenotype of BK-2R knockout mice and 
reported the development of LVH accompanied by only a moderate rise 
in blood pressure in these animals by 2 months of age. LVH progressed to 
fulminant heart failure in six months without an increase in blood pressure, 
suggesting that remodeling was the primary process unrelated to systemic 
hypertension (132).
Progressive degenerative and fi brotic changes were observed in the 
myocardium of -/- mice and similar but less prominent changes were detected 
in heterozygous BK-2R +/- mice. The knockout animals were also tachycardic, 
similar to rats with a prenatal blockade of BK-2Rs, suggesting that kinins are 
also involved in early programming of the cardiovascular phenotype (274). 
Increased myocardial weight and blood pressure at the base-line has been 
reported in knockout mice, though others have failed to repeat these results 
(11;275;448).
Duka et al. reported that BK-2R knockout-mice developed LVH and heart 
failure after myocardial infarction and that remodeling and cardiac dysfunction 
responded poorly to ACE inhibitor or ARB treatment. The same group later 
reported that ACE inhibition worsened the cardiac function in mice lacking 
BK-2Rs. This effect was linked to up-regulation of pro-infl ammatory BK-1Rs 
(122;124).
In BK-2R knockout mice, BK-1Rs are up-regulated and their sensitivity to 
stimulation is signifi cantly increased, which partially substitutes for the lack of 
BK-2Rs. Further, stimulation of BK-1Rs with an agonist provokes hypotension 
and antagonist-induced hypertension, suggesting an antihypertensive effect of 
BK-1Rs, possibly through inhibition of vasoconstrictors produced through the 
AA cascade (123;124).
Kakoki et al. reported that in the absence of BK-2Rs, Akita diabetic mice 
show an additive increase in oxidative stress, mitochondrial DNA damage, and 
other senescence-associated phenomena, implying that increased senescence 
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and apoptosis in actively dividing cells are related to BK-2Rs. The authors 
suggest that the increased oxidative stress and ROS are due to decreased 
intracellular NO production in BK-2R-defi cient diabetic mice (212).
The transgenic mice models have further verifi ed the role of BK-2Rs in 
hypertension. Over-expression of human BK-2Rs in mice induces hypotension, 
which can be negated by icatibant. Also rats that over-express human tissue 
kallikrein gene experience hypotension. Induced hypertension with subsequent 
LVH was signifi cantly reduced in hTK over-expressing rats compared with 
controls, and icatibant completely inhibited the effects (413).
3.3.2 BK-1 Receptor Models
The BK-1R knockout mouse was generated fi ve years later than the BK-2R 
KO (352). The lack of BK-1Rs has no effect on blood pressure or cardiac 
performance in physiological situations.
Induced myocardial infarction in BK-1R -/- mice did not signifi cantly 
infl uence myocardial remodeling (493). In another study BK-1R knockout 
mice showed higher coronary perfusion pressure, indicating higher coronary 
resistance. eNOS expression was also signifi cantly diminished in the aortas 
of -/- mice, which could explain their increased coronary resistance (249). 
BK-1R knockout-mice have a pain-phenotype that implicates a role for 
this receptor in infl ammatory and neuropathic pain. Knockout-mice exhibit 
reduced responses compared to wild types, in several pain models (143;352).
The absence of BK-1Rs in LPS-induced septic shock is associated with 
signifi cant hypotension and signifi cantly increased mortality (297).
The relevance of BK-1Rs in LPS-mediated septic shock has been 
intensively studied in knockout-models and the results have been confl icting: 
some report hypotension and others hypertension in septic BK-1R knockout-
mice (74;352). Experimental differences explain some of these discrepancies, 
and it has been suggested that the BK-1Rs are fi rst up-regulated in the initial 
phase of septicemia and are associated with vasoconstriction, implying that 
the BK1-Rs protect against acute, signifi cant hypotension, thus reducing 
mortality (406).
Reduced neutrophil migration to infl amed tissues as well as apoptosis of BK-
1R expressing neutrophils as a requirement for the resolution of infl ammation 
was reported in mice lacking BK-1Rs (352).
3.3.3 Double KO
Until recently, the close proximity of the genes encoding the two receptors has 
prevented the generation of double-KO mice. Surprisingly double- KO -mice 
are normotensive and their cardiovascular morphology is normal, supporting 
Liesmaa_Inka_Vaitosk.indd   41 12.1.2010   19:17:17
42
previous results indicating that under basal conditions, the kinin system does 
not play a signifi cant role in cardiovascular physiology, at least in mice (74).
Table I. The main (cardiovascular) eff ects of BK-Rs 
BK-1R BK-2R BK1R ref BK-2R ref
Vasodilation ++  (artery) ++ (103;120;297) (85;87)
Vasoconstriction ++ (vein) (1;163;369)  
SMC eff ects anti-proliferation anti-proliferation (112) (381)
VSMC contraction + ++ (109) (254;255)
Ischemic preconditioning + ++ (53;77) (61;89;468;475)
Angiogenesis + + (112;345) (133;310;443)
Fibroblast pro-fi brotic anti-fi brotic (181) (389;395;454)
Infl ammation chronic acute (68;73;298) (298)
Leukocyte traffi  cking  (35;296;352)  
Cytokine activation   (104;172) (173;270)
Endotoxic shock hypotension early 
hypotension
(103;297;371) (298)
Pain chronic acute (351;352) (67;117;351)
Thrombosis anti-thrombotic (59;361)
Bronchoconstriction + + (199) (37)
4. Smooth Muscle Cells
In addition to endothelial cells, the BK -receptors can also be detected in other 
cells, though it is believed that their major effects are contributed via ECs.
It is known that in smooth muscle cells, BK-2R stimulation causes 
vasoconstriction and contributes to vascular injuries. In denuded canine 
saphenous veins, direct induction of BK onto SMCs induced concentration-




In experiments with intact guinea pig aortic rings or arterial myocyte 
cultures, direct BK-2R stimulation leads to constriction.
When the vascular endothelium is damaged, stimulants can gain direct 
access to the receptors in the smooth muscle. In these circumstances it is 
possible that BK-Rs play a role in the regulation of vascular injury.
4. SMOOTH MUSCLE CELLS
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5. Angiogenesis
Angiogenesis is the process of forming new capillaries from existing blood 
vessels. It involves several steps that result in the formation of new vessels 
when the highly regulated balance is in favour of angiogenesis (149).
The pro-angiogenic effect of BK has been demonstrated in both in vitro and 
in vivo studies under different experimental settings (79;131;231;317;345). 
Some data on cardiac angiogenesis are also available, which show favourable 
effects of kinin receptors on angiogenesis. It was recently shown that 
angiotensin II induced angiogenesis in hypoxic mouse hearts in a BK-2R- and 
NO-dependent way that also involved AT-2Rs (322). Interestingly, neither Ang 
II nor VEGF could induce angiogenesis in BK-2R knockout-mice (322). BK-
2Rs transactivated the VEGF receptor (KDR/Flk1) in cardiac capillary ECs, 
resulting in further eNOS activation (443). Later the results were confi rmed 
with coronary endothelial cells, where BK induced tube formation through a 
BK-2R-KDR/Flk1-dependent mechanism. BK and VEGF were suggested to 
have a synenergistic effect on angiogenesis (310).
Angiogenesis has also been linked to BK-1Rs (345). The study showed that 
BK was able to activate BK-1Rs in rabbit corneal capillary endothelial cells 
by stimulating the eNOS/FGF-2-pathway. These results were confi rmed later 
in a study that showed a BK-1R dependent up-regulation of eNOS, and FGF-2 
was involved in microvascular coronary endothelial cell and migration was 
induced by ACE inhibitors (114).
Tissue kallikrein has been associated with angiogenesis in several transgenic 
studies.
Transduction of the human tissue kallikrein (hTK) gene into an ischemic 
myocardium stimulated arteriole and capillary growth, reduced apoptosis, 
and increased the number of cardiac progenitor cells. A transient increase in 
TK was detected and the Akt-eNOS-NO-pathways were activated through 
increased kinin production (133;176). Unfortunately, these studies did not 
explore the BK receptors responsible.
In another study, hTK gene delivery improved cardiac function and protected 
against cardiac remodeling in HF by attenuating cardiac hypertrophy, fi brosis, 
and LV enlargement and by promoting capillary formation. These effects were 
seemingly connected to kinin-BK-2R activation (6;48;505).
These studies suggest that BK modulates cell-signaling pathways through 
BK1-and/or BK2-receptors and thus plays a role in regulating angiogenesis. 
The specifi c mechanisms underlying angiogenesis and the signifi cance of BK 
receptors remain under debate.
5. ANGIOGENESIS




The endothelium is a continuous monolayer of cells linked to each other by 
different type of adhesive structures or junctions that cover the cardiovascular 
system. For a long time the endothelium was thought to be an inert layer 
covering the vessels but today we know that it is a dynamic structure that 
regulates and maintains cardiovascular homeostasis (315).
The endothelium is only 0.5 μm thick and rests on a thin basement 
membrane. The single cells are connected to each other by junctions (241). 
During embryonic development, endothelial cells differentiate from common 
precursor cells and acquire organ-specifi c properties. An important determinant 
of the cell differentiation is the local environment, and especially interactions 
with surrounding cells. These interactions may occur through the release of 
soluble cytokines, cell-to-cell adhesion, and communication or synthesis of 
matrix proteins on which the endothelium adheres and grows. Even in the 
same organ, the endothelium exhibits signifi cant heterogeneity (375).
Two types of endothelial cells are recognized in the heart: endocardial 
endothelial cells and microvascular endothelial (MVE) cells (241). Both cells 
produce the same autacoids and share a similar role in signal transduction. 
The huge difference between them is that the MVECs contribute to cardiac 
function indirectly by regulating regional blood fl ow, but the endocardial ECs 
function directly by communicating with myocardial cells.
The endothelium contributes to cardiovascular homeostasis by regulating 
vascular permeability and adjusting the caliber of blood vessels according 
to hemodynamic and hormonal demands. Endothelial cells perform these 
functions by expressing, activating, and releasing powerful vasoactive 
substances and other bioactive molecules. These substances include factors that 
affect vasoconstriction and -vasodilation, coagulation, thrombosis formation, 
growth, angiogenesis, and tissue remodeling as well as immune reactions and 
tissue infl ammation. The endothelium thus creates a complex and fi nely tuned 
balance of interactions with the immediate environment, which are common 
to all endothelial cells (204;380).
Despite its stable constitutive properties, a normal endothelium reversibly 
changes its function on activation. For instance, exposure of ECs to 
infl ammatory cytokines induces reprogramming of genes - activation of some 
and depression of others (280). Senescence of ECs infl uence endothelial 
responses, thus senescent cells have defective signaling pathways that lead to 
an inability to properly responds to stimulants such as growth factors (161).
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6.2 Endothelium -derived Vasoactive Substances
Endothelial cells secrete vasodilating mediators in response to substances 
released from autonomic and sensory nerves, circulating hormones, coagulation 
derivates, or autacoids such as bradykinin, angiotensin, and endothelin, secreted 
by endothelial or smooth muscle cells. Some of these vasodilating substances 
possess angiogenic and growth-modulating properties. Infl ammation, vascular 
lesions, and thrombosis often accompany impaired vasodilation. It is generally 
accepted that the net effect of noxious substances and vasoactive, retrieving 
substances dispose the condition of the endothelium. Thus, there are several 
mending mechanisms in the endothelium that oppose dysfunction -promoting 
stimuli, of which the most important ones are mentioned here.
Activation of the kinin receptors induces three of the important mechanisms 
by which the endothelium reacts by vasodilation, as shown in Fig 8.
Fig 8. A schematic view of the mechanisms of BK-BK-2R activation in the endothelium
6.2.1 Nitric Oxide
Nitric oxide (NO) secreted by vascular endothelial cells is a ubiquitous 
signaling molecule that is able to diffuse across membranes, producing various 
physiological effects, of which the most important effect is vasodilation 
(200;343). Three different NOS isoforms have been described, named after 
the cell type fi rst isolated. They differ in tissue expression, regulation and 
the average amount of NO produced. The endothelial (eNOS) and neuronal 
(nNOS) isoforms are constitutively expressed; iNOS is induced under 
pathological conditions and can produce vast amounts of NO. The synthesis 
Liesmaa_Inka_Vaitosk.indd   45 12.1.2010   19:17:19
46
of NO requires L-arginine as a substrate and binding of Ca2+ / calmodulin. 
BK also stimulates NO production through Ca2+/calmodulin-mediated eNOS 
activation.
The NO synthases are NADPH-dependent oxygenases that require several 
co-factors.
eNOS is the dominant enzyme in vascular cells and it is localized in the 
endothelial caveolae and negatively regulated by caveolin. Indeed eNOS 
seems to be mainly regulated by modulation of its activity, e.g. by protein 
kinases (MAP, Akt) (162;171). The inducible NO synthase (iNOS) is 
primarily regulated transcriptionally and is independent of agonist stimulation 
or intracellular calcium level (162;171).
A lack of NO is a predominant fi nding in endothelial dysfunction, which 
can be created by blocking eNOS and ameliorated by introducing nitrates. 
Activation of BK-2Rs, but also BK-1Rs, stimulates eNOS to produce NO, 
leading to vasodilation (132;493).
6.2.2 EDHF
The endothelial-derived hyperpolarizing factor (EDHF) contributes to 
vasodilation and involves BK-2Rs. Many molecules have been suggested 
as being the EDHF, and lately the notion has focused on arachidonic acid 
metabolites, mainly epoxyeicosatrienoic acids (EETs). The origin of the EDHF 
is still unclear (148). The effect of the EDHF has been demonstrated in various 
blood vessels from different species, including humans, and it likely plays an 
important role in cardiovascular physiology. In human coronary arteries, the 
importance of the EDHF seems to increase as the arterial diameter decreases 
(461). EDHF-mediated responses are clearly altered in various pathological 
conditions such as heart failure, atherosclerosis, and hypertension (140).
6.2.3 PGI2
The vasodilating prostaglandin -prostacyclin (PGI
2
)- is primarily produced by 
ECs (316). BK-2R stimulation activates PGI
2
 release through the PLA
2
 and 
arachidonic acid pathway (AA). However, unlike NO, the vasodilating effects 
of PGI
2
 are determined by the expression of specifi c cyclo-oxygenases (COX-1 
and COX-2) in vascular smooth muscle cells, and if the arteries do not express 
these binding receptors, prostacyclin can not participate in vasodilation (91). 
Receptor activation in SMCs elevates cyclic nucleotide levels, inducing hyper-
polarization thus inhibiting vasocontraction. The link between NO and PGI
2
 
is bidirectional: prostacyclin can ease the release of NO from ECs and NO 
potentiates the effect of prostacyclin in vascular SMCs (106;409).
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is another prostaglandin participating in a wide range of 
cardiovascularfunctions, such as vasoconstriction and vasodilation, control 
of blood pressure, regulation of smooth muscle tone and modulation of 
infl ammation. It has been connected to angiogenesis, though the mechanisms 
are not completely understood, thus PGE
2
 does not stimulate EC migration 
(187;417), but can induce vascular endothelial growth factor (VEGF) 
expression and thus relate to angiogenesis via VEGF (417).
6.3 Endothelial Dysfunction
Endothelial dysfunction refers to a pathophysiological state where there is an 
imbalance between the endothelium-derived relaxing and contracting factors 
and the availability of NO, in particular, is diminished (466).
This imbalance leads to reduced vasodilation and to activation of 
pro-infl ammatory and pro-thrombotic processes, promoting endothelial 
dysfunction. 
Endothelial dysfunction plays a central role in the initiation and progression 
of cardiovascular diseases in which the pathophysiological end point is 
alteration of vascular homeostasis, which leads to diminished tissue blood 
supply. Diseases like heart failure, coronary arterial disease, and hypertension 
are all associated with endothelial dysfunction, where diminished availability 
of NO and increased reactive oxygen species (ROS) formation is detected. 
EC dysfunction is also related to factors such as smoking, hyperglycemia, 
and hypercholesterolemia, which are all major risk factors of cardiovascular 
diseases, but are also connected to the kinin system. Despite the many provoking 
factors, by far the most important perpetrator of endothelial dysfunction is 
hypoxia.
6.3.1 Hypoxia 
The origin of various vascular pathologies involves instant or recurrent oxygen 
defi ciency. Hypoxia activates endothelial cells by means of a complex system 
that varies between species, but also between cell types, where the same hypoxic 
effect can induce different signaling. At fi rst the activation can be viewed as 
adaptive or protective, but if the stimulus is severe or last long enough, the 
reaction changes into a maladaptive or lethal one. Following acute hypoxia, 
endothelial cell activation, neutrophil adherence with local infl ammation, 
and enhanced production of cytokines (IL-6, IL-1β, MCP-1) are observed, 
accounting for the infl ammatory response in ischemic tissues (412).
Hypoxia increases the cytosolic calcium concentration that regulates many 
enzymes and participates in signal transduction, such as phospholipase A
2 




), which increases in hypoxic ECs, leading to prostaglandin synthesis 
(20;306). It also up-regulates COX-2 through the induction of NF-kappa-β 
expression, which also induces ECs to secrete prostaglandins (400).
Even though the endothelial cell layer is relatively tolerant of low oxygen 
tensions, many of the effects of chronic hypoxia are thought to take place 
through alterations of endothelial cell signaling. Hypoxia directly affects 
the release of vasoactive nitric oxide (NO), which locally regulates vascular 
smooth muscle tone (473), though the physiological mechanisms regulating 
NO production in the vasculature are not completely understood. Confl icting 
results on eNOS expression and regulation under hypoxia have been presented 
and the results seem to vary between species and organs (301;434).
Together with eNOS, also iNOS can be induced in endothelial cells, so the 
net effect of NO production is even more complicated (342).
In chronic hypoxia, the expression of growth factors, cytokines, and 
molecules participating in the coagulation process is augmented, affecting 
remodeling of the vascular wall and myocardium. Many mitogenic molecules 
released by ECs induce smooth muscle proliferation in vascular beds (338). 
By far the most potent mitogen in ECs is the vascular endothelial growth 
factor (VEGF), which initiates angiogenesis in vivo. Hypoxia up-regulates the 
VEGF, but also its receptor, which may explain the strong mitogenic response 
during hypoxia (476).
Hypoxia transcriptionally induces several genes. The major regulator in 
cells and tissues is the hypoxia-inducible factor (HIF), an oxygen-sensitive 
transcription activator. The complex of HIF consists of two proteins: hypoxia 
-induced HIF-1α and constitutively expressed HIF-1β. The activated 
complex is associated with a specifi c binding site in target genes and it binds 
transcriptional co -activators to induce gene expression (214). Today there 
are over a hundred HIF downstream genes identifi ed, and more that 2% of all 
human genes are directly or indirectly regulated by HIF in arterial endothelial 
cells (277). HIF participates in multiple physiological responses to hypoxia, 
such as erythropoiesis, glycolysis, angiogenesis, and apoptosis.
Many genes, such as VEGF, involved in angiogenesis are activated in 
hypoxia and regulated by the HIF. The levels of HIF-1α and VEGF are up-
regulated in the myocardium of patients with acute coronary occlusion (250). 
Effective vascular remodeling in ischemic injury depends on an integrated 
program of HIF-dependent gene expression (223). Although the HIF is 
activated in situations where also the kinin system is activated, there are no 
data relating these systems.
6.3.2 Other Factors Contributing to Endothelial Dysfunction
Hypercholesterolemia induces impairment of endothelium-dependent 
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vasodilation. Oxidized low-density lipoproteins (LDL) down-regulate the 
expression of eNOS protein and inhibit the release of both NO and the EDHF, 
leading to impaired vasodilation (129;472). By disturbing the balance in the 
endothelium, LDL promotes several vasoconstricting factors (259).
Hyperglycemia with or without insulin defi ciency is a major contributor 
to endothelial dysfunction. Hyperglycemia and its biochemical sequelae 
directly affect the endothelial function, but also the synthesis of vasoactive 
substances, growth factors, and cytokines. It is not clear whether impaired 
endothelial function is due to hyperglycemia or other factors. It is also closely 
associated with the presence of insulin resistance, regardless of the presence 
of diabetes.
In hypertension there is an imbalance between the vasoconstrictory 
and vasodilatory-systems, in particular a reduced vascular availability of 
endothelium -derived NO. In SHR aorta the endothelium induces cyclo-
oxygenase-related contraction of the underlying vascular smooth muscle cells 
in response to contracting factors. Patients with essential hypertension have 
impaired dilatory responses to BK and other stimulants, which can be partially 
restored by indomethacin (466). Impaired BK -dependent vasodilation in 
hypertension is also found in normotensive people with a family history of 
hypertension (432). Several other factors, such as renal insuffi ciency, aging, 
smoking, hyper-homocysteinemia, and estrogen-defi ciency, also contribute to 
endothelial dysfunction (330).
6.3.3 Endothelial Dysfunction in Heart Failure
Endothelial dysfunction has been presented in cardiac failure in both animals 
and humans (222;440). It is found in HF patients with normal coronary 
circulation or no predisposing factors, suggesting that dysfunction could 
represent an independent factor in the development of HF (335;449). These 
patients have impaired relaxation of the coronary microvasculature and 
peripheral vasculature, but enhanced basal production of NO (237). The 
relaxation is heterogeneously affected in different vascular beds (335). The 
damped vasodilating reaction in HF patients together with the release of 
vasoconstricting substances facilitates poor perfusion and ischemia of the 
myocardium (118;335).
In animal models, the induction of LVH up-regulates the expression of 
eNOS.
However during the transition to HF, the expression of eNOS also reduces 
the secretion of NO (170). This regulation of eNOS has been shown in human 
end-stage HF and is consistent with BK-2R expression in the progression of 
HF (239;240).
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7. Treatment
The treatment of cardiovascular diseases has progressed during the last 
decades. As knowledge about the diseases and the molecular mechanisms 
involved has increased, more possibilities have become available. Despite 
the increased knowledge and treatment of heart failure, the prognosis has not 
improved much.
The medical treatment of HF consists of diuretics and vasodilating drugs, 
such as nitroglycerin, which both relieve the symptoms but have no impact 
on the prognosis of HF. The β-blockers, previously believed to increase the 
mortality in HF, are now recommended for the treatment of HF together with 
diuretics and ACE inhibitors, and shown to have both symptom relieving but 
also mortality reducing effects also in HF (110). ACE inhibitors/AT-1 receptor 
inhibitors and statins are widely used in the treatment of HF and they will be 
discussed here more closely.
7.1 Statins
Statins are in many ways intriguing drugs that were originally developed to 
lower plasma cholesterol.
Cholesterol is an essential component of cell membranes and also 
a precursor of steroid hormones and bile acids. However, in excessive 
quantities, cholesterol becomes a major risk factor of cardiovascular diseases. 
The rate -limiting enzyme of cholesterol biosynthesis in the liver is HMG-
CoA reductase, which catalyses the conversion of HMG-CoA into mevalonic 
acid (mevanolate) (Fig 9.). Inhibitors of HMG-CoA reductase, statins were 
isolated in 1976 from Penicillium citrinium, later named as mevastatin (134). 
A few years later a more potent substance, lovastatin, was isolated and later 
approved for clinical use. Since then, several new potent statins have been 
developed and they are today in wide clinical use.
Statins are potent drugs that cause a dramatic reduction in circulating LDL-
cholesterol and an increase in LDL clearance. However, increasing data show 
that the benefi cial effects of statins are only partially cholesterol -dependent 
and possess many cholesterol-independent or pleoitropic effects.
The Framingham heart study demonstrated that elevated cholesterol is an 
important risk factor of cardiovascular diseases. The mechanisms attributed to 
lipid lowering with statins include modifi cation of atherosclerosis progression, 
atheromatous plaque stabilization, and improved endothelial function. Hence, 
statins reduce cardiovascular events in both hypercholesterolemic and 
normocholesterolemic patients with coronary heart disease.
In several studies (4S, CARE, HOPE, LIPID, WOSCOPS) statins have 
demonstrated benefi cial effects in both primary and secondary prevention 
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of cardiovascular diseases. They also improve heart function and survival in 
patients with non-ischemic heart failure (194;331). It has been suggested that 
short-term statin therapy improves cardiac function, neurohormonal imbalance, 
and symptoms associated with idiopathic dilating cardiomyopathy, suggesting 
that a non-cholesterol -dependent mechanism is involved (150;194;331). 
On the other hand, there are also hypotheses, which compromise the benefi cial 
effects of statins in HF, of which the lipoprotein-endotoxin -hypothesis is well 
known (366).
Fig 9. The cholesterol pathway
By inhibiting the conversion of HMG-CoA to mevanolate, statins prevent 
the synthesis of important isoprenoids such as farnesylpyrophosphate 
(FPP) and geranylgeranylpyrophosphate (GGPP), which are precursors of 
cholesterol but also serve as important intermediate lipid attachments for 
translational modifi cation of a variety of proteins including small guanosine 
triphosphate (GTP)-binding proteins Ras, Rho, Rac, and Rab (464). (Fig. 9.) 
Protein isoprenylation permits covalent attachment, subcellular localization, 
and intracellular traffi cking of membrane-bound proteins. Members of 
the Ras and Rho-GTPase families are important substrates for prenylation, 
and statins inhibit this action, leading to accumulation of inactive Ras and 
Rho proteins in the cytoplasm (464). The Rho GTPase -family consists of 
RhoA, Rac, and Cdc 42 protein subfamilies. The overall functions of Rho 
GTPases are related to cell shape, motility, secretion, and proliferation. Thus, 
statins induce a change in the three-dimensional actin cytoskeleton, affect 
intracellular transport, membrane traffi cking, and mRNA stability as well as 
gene transcription (246). The activation of Rho and its downstream target-
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Rho-associated -protein kinase (ROCK) - increases the sensitivity of vascular 
smooth muscle cells to calcium in hypertension and coronary spasm (218;460). 
The activation is connected to smooth muscle contraction, oxidative stress, 
aortic stiffness, and changes in blood pressure. The pathway is also involved 
in myogenesis, angiogenesis, adipogenesis, cardiac hypertrophy, hypertension, 
and perivascular fi brosis as well as in the activation of infl ammatory cytokines 
and chemokines (333;423;460).
The Rac pathway is connected to the formation of reactive oxygen species 
(ROS) and cytoskeleton formation. The growth factor and cytokine -generated 
ROS are mediated by Rac, and the activation of Rac in the vascular wall is 
associated with atherosclerosis, myocardial hypertrophy, and endothelial 
dysfunction (169).
By inhibiting these (Rho and Rac) pathways, statins create non-cholesterol 
-dependent, pleoitropic effects that seem to be an important factor in 
cardiovascular protection. The positive effects have also been exhibited by 
inhibiting the GTPases individually, thus promoting cardioprotective effects 
such as endothelial function improvement or inhibition of atherosclerosis 
(276;332).
Statins affect eNOS expression and NO production in many ways. They affect 
eNOS expression by stabilizing its mRNA and reduce the binding of eNOS to 
caveolin-1, which as a complex reduces NO formation and activates the PI3K/
Akt pathway, where Akt induces eNOS activation and NO production. Statins 
also restore eNOS activity in hypoxia and hypercholesterolemia (244;332).
Retrospective analysis of large statin trials, such as 4S, suggests that 
statins also reduce the incidence of heart failure (229). Recently two small 
prospective studies showed benefi cial effects of statins in human heart failure. 
These patients showed improved cardiac function and reduced symptoms 
(248;331).
On the other hand, in the latest CORONA study, rosuvastatin failed to 
decrease mortality in elderly heart failure patients (228). The GISSI-HF study 
unfortunately displayed similar results, in patients treated with rosuvastatin 
(439).
Statins exert many effects beyond cholesterol lowering, which include 
diminished endothelial dysfunction, vascular infl ammation, and inhibition 
of smooth muscle cell proliferation. These same molecular mechanisms can 
also be connected to kinins and their receptors, but there is no information 
concerning BK receptors and statins.
7.2 ACE and AT-Receptor Inhibitors
Angiotensin-converting enzyme inhibitors (ACEI) are effective anti-
hypertensive agents, but also very potent in treating and preventing heart 
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failure. They are also powerful agents in treating and preventing MI, stroke, 
diabetes, and renal failure.
The protective effects of ACE inhibitors are due to their blocking the 
formation of Ang II and inhibiting the degradation of BK. Increased BK levels 
enhance NO synthesis and prostaglandin release through activation of BK-2Rs 
(232). ACEIs potentiate the effects of agonists on BK-2 receptors by inducing 
protein-protein cross talk between ACE and BK-2 receptors (283). They can 
also directly activate BK-1Rs (202). The antifi brotic effect of ACE inhibitors in 
heart failure are partly mediated by BK-2Rs (156). Many of the cardiovascular 
effects of ACEIs can be blocked by BK-2R antagonists or mimicked by 
exogenous BK, suggesting that the effects are mediated by the potentiation of 
bradykinin and/or BK-2Rs, rather than inhibition of Ang II conversion (232)
The effects of kinins with AT-1R inhibitors (ARBs) are thought to be 
mediated via activation of AT-2Rs. This activation seems to antagonize several 
effects induced by stimulation of AT-1Rs such as vasoconstriction, cellular 
growth, and hypertrophy (404). With AT-1R inhibitor treatment the increased 
concentrations of angiotensin II and its metabolites act on AT-2Rs and activate 
local kinin formation. They may also act on the kinin degrading enzymes to 
increase the tissue BK level (477).
Experimental studies show that kinins are also involved in the effects 
of AT-1R inhibitors. In an animal study where MI was induced to rats, 
losartan prevented LVH and HF and the effects were partly attenuated by 
concomitant inhibition of BK-2Rs (266). During the development of HF 
following myocardial infarction, BK-2R knockout-mice showed diminished 
improvement in cardiac function in response to AT-1R inhibitors than control 
mice (500). In mice that over-express AT-2Rs, infusion of Ang II induces 
hypotension, which can be abolished by icatibant (458).
The coupling between AT-2R and kallikrein during AT-1R inhibitor 
treatment and the increased plasma Ang (1-7) levels, which are known to 
potentiate the effects of bradykinin, may also contribute to the mechanisms 
related to AT-1R inhibitor-kinin cardioprotection (5;304).
Mounting evidence indicates that kinins are involved in the cardioprotective 
actions of ACE- and AT -receptor inhibitors the effects are mainly transmitted 
by BK-2Rs.
7.3. Anti-infl ammatory Agents
7.3.1 COX -Inhibitors
Non-steroidal anti-infl ammatory drugs (NSAIDs) block the activity of both 
COX isozymes, COX-1 and COX-2, which mediate enzymatic conversion of 
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membrane-derived arachidonic acid (AA) to prostaglandin H2 (PGH
2
) and 













). These prostanoids have cardiovascular effects – they can act as 
either vasodilators or vasoconstrictors, they infl uence thrombosis formation 
via platelets, and they alter renal functions. The inducible isoform- COX-2 - is 
expressed at sites of infl ammation such as atherosclerosis.
Fig. 10  The prostaglandin synthesis. 
Prostaglandins are widely recognized as infl ammatory mediators, but they 
can also regulate vascular contractility. COX-inhibitors are used as anti-
infl ammatory and pain relieving mediators. Cyclooxygenase-2 selective 
inhibitors (COXIBs) were developed with the prime objective of minimizing 
gastrointestinal adverse effects, which are seen with the use of traditional non-
steroidal anti-infl ammatory drugs (NSAIDs). During recent years several trials 
have connected COXIBs to unfavorable effects on cardiovascular outcomes 
and to increased risk of thromboembolic complications (334;421). At the same 
time there are controversial results suggesting that inhibition of COX-2 might 
be cardioprotective. To the latter belongs the fact that COX-2 can be detected 
from atherosclerotic lesions but not from normal coronary arteries (26). COX-2 
knockout-mice develop myocardial fi brosis (111) and the expression of COX-
2 seems to be up-regulated by atherosclerosis-inducing stimuli, including free 
radicals and increased arterial wall shear stress (3;492). And fi nally, because 
infl ammation of the endothelium is known to diminish its NO -producing 
capacity, COX-2-inhibition was shown to improve NO production in CHD 
and hypertensive patients (83;482).
Despite the numerous studies, any conclusion about their cardiovascular 
safety is complicated due to the confl icting results.
Atherosclerosis is a process with infl ammatory features, and selective cyclo-
oxygenase-2 (COX-2) inhibitors may potentially have anti-atherogenic effects 
Liesmaa_Inka_Vaitosk.indd   54 12.1.2010   19:17:23
55
by virtue of inhibiting infl ammation. However, by decreasing vasodilatory 
and anti-aggregatory prostacyclin production, COX-2 antagonists may lead to 
increased pro-thrombotic activity (167)
The connection with the kinin system has been suggested earlier. BK is 
know to induce COX-2 expression in different cell types, such as endothelial 
and smooth muscle cells (54;55). Indomethacin, an unselective COX inhibitor, 
was able to cause potentiation of BK-induced contraction of both isolated rat 
uterus and guinea pig tracheal SMC preparations (80;398).
Down-regulation of BK-2Rs has been detected in rabbit hearts treated with 
a non-specifi c COX inhibitor, suggesting kinin-prostanoid-induced regulation 
of BK-2Rs (281).
It was recently also shown that BK induced COX-2 expression in aortic 
vascular smooth muscle cells, and the effect was mediated by BK-2Rs and 
involved MAPK p42/p44, PKC, and eNOS activation (379).
Clearly, there are interactions between kinin and prostanoid systems, 
and the involved kinin receptor seems to be BK-2R, but again, the specifi c 
mechanisms and clinical relevance need further studies.
8. BK- Receptors in Heart Failure 
Considerable progress has been made in understanding the biology and 
function of bradykinin receptors. A large body of animal studies implicates 
a role for BK receptors in vascular pathophysiology. Little is directly known 
about the clinical relevancy of kinin receptor activation in humans, though an 
increasing amount of data indicates a cardioprotective role for kinin receptors 
in humans, also. Direct evidence of BK-receptor involvement in cardiovascular 
diseases is diffi cult to acquire, as the vascular segments needed for direct 
receptor observation are fairly diffi cult to obtain. Thus, the involvement of 
kinin receptors is mostly suggestive and based on receptor agonist/antagonist 
studies or detection of secondary pathway induction. Knockout-models have 
also provided valuable information about the regulation and function of BK 
receptors.
8.1 Lessons from Human Studies 
8.1.1 BK-2 Receptors
In a prospective study with healthy army recruits, a ten-week physical training 
program, associated with LV growth response and BK-2R +9/-9 polymorphism 
and increased LV mass related to the +9/+9 genotype (60). The absence (-) of 
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a 9 bp repeat in exon 1 of the gene encoding the bradykinin 2 receptor is 
associated with higher receptor mRNA expression, higher gene transcriptional 
activity and lower cardiac trophic response to exercise training (56;60). 
Similar results were obtained from patients suffering from hypertension and 
LV hypertrophy. The +9/+9 genotypes responded worse than other genotypes 
to LV mass regression, independent of blood pressure reduction or treatment 
(174). There was also a strong link to ACE I/D polymorphism, suggesting a 
synergistic effect between kinin receptors and ACE. The results support the 
role for bradykinin in the regulation of left-ventricular growth (60).
Several studies associate BK-2R promoter region polymorphism -58 
T/C and hypertension, where the C-allele is associated with LVH and/or 
hypertension at least in African-Americans, Japanese and Chinese subjects 
(141;155). African-Americans have a signifi cantly increased prevalence, 
earlier onset, increased mortality in HF, and worse endothelial dysfunction, 
which could at least partly be explained by the 58 T/C polymorphism and the 
decreased activity of cardioprotective BK-2Rs. Also, a signifi cantly higher 
incidence of the C allele of BK-2R was seen in hypertensive patients suffering 
from myocardial infarction in a Japanese study (18). There is no signifi cant 
difference in the 58 T/C polymorphism, in the European population; the 
frequency of the C allele is 0.595 and for the T allele is 0.405, which are in 
Hardy-Weinberg equilibrium (56;174).
So far, the only human study on heart failure patients and BK-2 receptors 
was done a few years ago. In human end-stage heart failure patients, a decrease 
in BK-2Rs in both protein and mRNA levels was observed in the left ventricles 
of end-stage heart failure patients. There seemed to be no differences in cell-
specifi c expression of BK-2Rs between normal and diseased hearts. The 
subsequent down-regulation of eNOS suggests a maladaptive connection 
between these two proteins (239).
The role of kinins in heart diseases has not received much attention, 
despite the fact that in the 1960s it was shown that both local and systemic 
administration of BK increased coronary blood fl ow and improved myocardial 
metabolism. It took almost 30 years to observe the same in humans. Infused 
BK doubled blood fl ow in the human forearm; the effect was abrogated by 
BK-2R antagonist icatibant (87).
The TREND (trial on reversing endothelial dysfunction) trail showed 
that ACE inhibitor treatment improved NO-mediated endothelial function in 
CHD patients. The results were confi rmed in healthy and HF patients, where 
improved endothelial function was abolished by icatibant, indicating the 
signifi cant role of kinins and BK-2Rs in the endothelium and cardiovascular 
diseases (192;193;278).
In atherosclerotic patients BK-induced vasodilation is impaired in the 
plaque area but preserved in spastic areas, suggesting that the EDHF might 
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have a role in vasodilation in CHD patients. These results were previously 
suggested in animal models (238;313;441).
A clear correlation between brachial dilation and epicardial dilation was 
established when bradykinin was infused into subjects with no signs of CHD, 
who were undergoing coronary angiography (290). Flow-mediated impaired 
dilation of the brachial artery is considered a non-invasive assessment of 
coronary endothelial dysfunction. Also in patients undergoing coronary 
angioplasty (PTCA), infusion of BK mimicked the effects of an ischemic 
precondition rendering the myocardium relatively resistant to subsequent 
ischemia (252).
Several studies have demonstrated that the serum of patients with heart 
failure can alter the function of endothelial cells by down-regulating the 
expression of endothelial nitric oxide synthase (7). Unfortunately, the role of 
BK-2Rs was not reported in these studies. ACE inhibitors improve endothelial 
vasomotor dysfunction in patients with coronary disease, and the effect is 
mediated by BK-2Rs (360).
Icatibant reduced the hypertensive effect of captopril (ACEI) in patients 
with hypertension by 53 percent (159).
8.1.2 BK-1 Receptors
Knowledge about BK-1Rs in human heart failure is scarce. Infusion of a 
promiscuous B1-B2-R antagonist (B9340) decreased forearm blood fl ow in 
HF patients taking ACE inhibitors. The effect was absent in patients with no 
ACE inhibitors as well as in a control group. Icatibant failed to dilate forearm 
blood fl ow, thus suggesting that BK-1Rs were mediating dilation in congestive 
heart failure concomitant with ACE inhibition (487).
In 1997 Raidoo et al. discovered that atheromatous arteries exhibit 
more intense BK-1R labeling in the endothelial cells, foamy macrophages, 
infl ammatory cells, and fi broblasts within plaque and in the intima (364). This 
suggests that BK-1Rs are relevant in CHD. No other reports on this matter 
have been published since (364).
Two small studies recently showed that BK-1Rs did not have a major role 
in peripheral circulation in HF patients, nor could they show any cross-talk 
between BK-1 and BK-2 receptors (97;245).
The role of BK receptors in human heart failure is not convincing. Although 
there are numerous studies concerning kinins, knowledge about kinin receptors 
is weak. To complicate the issue, results from different animal studies have 
been somewhat controversial, which may at least partly be explained by the 
different species involved and the different expressions of receptors.
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8.2 Lessons from Animal Studies
8.2.1 BK-2 Receptors
The number of BK-2Rs was dramatically decreased during the progression of 
heart failure in a pressure overload model in spontaneously hypertensive rats 
(SHR). The number of receptors fi rst increased, correlating to the progression 
of LVH without fi brosis or ventricular dysfunction. Marked fi brosis and LV 
dysfunction were observed in the failing hearts, with a loss of BK-2Rs mainly 
located in the vascular endothelial cells, suggesting a role of the BK-2Rs in 
end-stage HF. Similar results were obtained from experiments in which acute 
pressure overload (aortic banding/Ang II infusion) induced the heart failure 
(240).
ACE inhibitors are the basis of medication in heart failure. Treatment with 
ACE inhibitors affects BK-2R regulation and potentiates its responses in many 
ways, not only by inhibiting kinin degradation (284;309). Numerous studies 
show that the positive cardiovascular effects of ACEIs are partly transmitted 
via BK-2Rs.
To elucidate the role of BK-2Rs, an orally active BK-2R antagonist 
(FR173657) was administered to dogs with HF under long-term concomitant 
treatment with ACEI. 
Inhibition of BK-2Rs did not alter systemic blood pressure or LV chamber 
dimension. Increased LV fi lling pressure and suppressed expression of eNOS 
and sarcoplasmic reticulum Ca 2+-ATPase mRNA were detected as well 
as up-regulation of collagen I and III expression. Collagen deposits were 
increased in the myocardium of the failing hearts in the BK-2R antagonized 
group, indicating a detrimental role for BK-2Rs in the progression of HF. 
The treatment did not alter systemic blood pressure or vascular resistance in 
HF dogs, suggesting also that endogenous BK does not participate in blood 
pressure regulation via BK-2Rs (156).
BK inhibited the progression of cardiac hypertrophy and myocardial 
fi brosis in hypertensive rats due to activation of BK-2Rs (437).
Chronic infusion of bradykinin was also able to preserve ventricular and 
endothelial function in conscious dogs, while delaying the progression of 
heart failure (447).
The role of BK-2Rs in ischemic preconditioning has been observed in 
several studies.
The positive effects are reduced infarct size and elimination of post-
ischemic arrhythmias by icatibant in preconditioned rats, rabbits, and mice. 
The positive preconditioning effects are not evident in BK-2R knockout mice 
nor in kininogen -defi cient Brown Norway rats, indicating the signifi cance of 
the kinin system to cardioprotection in I/R injury (468;501).
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BK seems to have a preventive role in the progression of HF, and the effects 
seem to relate to activation of BK-2Rs and involve NO and also the EDHF, 
both induced by BK-2Rs.
8.2.2 BK-1 Receptors
BK can exert cardioprotective effects via BK-1Rs, which are known to be 
involved in the BK-induced reduction of catecholamine release in ischemic 
rat hearts and in the maintenance of endothelial function in preconditioned 
hearts (53;77).
There are controversial results concerning the regulation and effects 
of BK-1Rs in myocardial ischemia. Contradictory results concerning the 
cardioprotective role of BK-1Rs in myocardial ischemia have been obtained 
from BK-1R KO-models (242;249;493).
Myocardial sympathetic fi bers express BK-1Rs and release noradrenalin. 
BK inhibits noradrenalin release in a BK-2R dependent way in ischemic rat 
hearts.
This inhibition was only observed in the presence of BK-1R antagonists, 
suggesting that BK-1R activation, induced by hypoxia, is involved in 
myocardial NA release (77;152).
9. Aims of the Study
The general hypothesis of the study was that the kinin receptor system, notably 
BK-2Rs and BK-1Rs, plays an important role in the pathophysiology of left 
ventricular hypertrophy and participate in the pathogenesis and progression 
of heart failure.
The aims of the study were to investigate the regulation of kinin receptors 
in normal and failing heart tissues, and in particular, in coronary artery 
endothelial cells. More specifi cally the aims were:
1. To clarify the expression of BK receptors in normal and failing human 
heart tissue.
2. To compare the accumulation of two known BK-2R gene polymorphisms 
affecting gene expression in normal and failing human hearts.
3. To investigate the regulation of BK-receptors in human coronary 
endothelial cells by both physiological and pharmacological factors, 
including hypoxia and lovastatin. 
9. AIMS OF THE STUDY
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10. Materials and Methods
The biochemical methods central to this thesis and their use in the original 
publications are summarized in table 2.
The methods are only briefl y described here, and detailed descriptions with 
references are provided in the Methods sections of the original publications.
Table 2. Methods used in the original publications
Method Publication
Preparation of human heart samples I, IV
RNA isolation I, II, III, IV
Competitive RT-PCR I, III
Real-time RT-PCR II, III
Protein extraction I, II, III
SDS-PAGE gel electrophoresis I, II, III
Culture of human endothelial cells I, II, III
Isolation of rat endothelial cells III
Culture of rat micro vascular endothelial cells III
Histological staining I, III
Immunocytochemistry II, III
cGMP immunoassay II
NO measurement II, III
“Wound healing” assay III
Human Heart Samples (I, IV)
Normal heart samples (n=6) were obtained from the left ventricles of organ 
donors who had no history of cardiac disease and had been excluded from 
organ donation because of age, body size, or tissue-type mismatch. The 
cause of death in these subjects was subarachnoid hemorrhage. The failing 
left ventricles were harvested at the time of cardiac transplantation from 13 
patients with end-stage heart failure (New York Heart Association functional 
class IV) due to either idiopathic dilated cardiomyopathy (IDC; n = 7) or 
coronary heart disease (CHD; n= 6) at the University Central Hospital, 
Helsinki, Finland. All the patients had been treated with a combination of 
drugs, including beta-blockers, ACE inhibitors, loop-diuretics, digoxin, and 
spironolactone. None of the patients had received angiotensin II type I receptor 
blocker treatment or statin treatment. After excision, the heart tissues were 
immediately frozen in liquid nitrogen and stored at –70 °C. The left ventricle 
myocardium devoid of visible scar tissue was used in the experiments. An 
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institutional review board approved the use of normal and failing human 
heart samples, and the investigation conforms to the principles outlined in the 
Declaration of Helsinki.
RNA isolation and PCR (I-IV)
Total RNA was isolated from both hearts and cell cultures using an ultrapure 
TRIzol reagent (GIBCO-BRL) and a RNeasy Mini Kit (QIAGEN). Purifi ed 
total RNA (0.25 μg for RT-PCR and 1 μg for real-time RT-PCR) was transcribed 
into cDNA using a Superscript preamplifi cation system (GIBCO-BRL).
Competitive RT-PCR was performed in 25 μl of a standard PCR buffer 
containing 1 μl of the RT reaction mixture, 25 pmol of sense and antisense 
primers, 100 μM of each deoxynucleotide, 0.5 units of Taq DNA polymerase 
(Roche), and competitor DNA. The primers used were BK-1R, BK-2R, 
TNF-α, and GAPDH as the housekeeping gene. The competitor DNAs for 
BK-1R, BK-2R, and TNF- α were obtained by subcloning the obtained PCR 
fragments and inserting a 129-bp external DNA fragment into the SmaI, SacI, 
and AvaI sites of the respective PCR fragment. The PCR fragments were 
verifi ed to represent the corresponding targets either by specifi c restriction 
enzyme treatment or by DNA sequencing. The PCR products were quantitated 
with a gel documentation system (Gel Doc 2000; Bio-Rad, Hercules, CA), and 
when a competitive method was used, the logarithm of target-to-competitor 
ratio was plotted against the logarithm of the competitor DNA molecules.
For real-time RT-PCR the DNA and mRNA sequences of the target genes 
were retrieved from the GenBank® database (National Institutes of Health, 
Bethesda, MD) and gene-specifi c primers and fl uorogenic probes were 
identifi ed with the Primer Express® software package. The primers used were 
BK-1R, BK-2R, and GAPDH as the endogenous control. The analyses were 
performed in 96-well plates (Applied Biosystems) using a TaqMan© Universal 
Master Mix with uracyl-Ν-glycosylase treatment in 25 μl reaction volumes. 
They were analyzed with an ABI Prism 7500 Sequence Detection System 
using 45 cycles of a two-step program consisting of 15 s at 95 °C and 1 minute 
at 60 °C. The threshold was set to the geometric phase of the amplifi cation 
curve, and the amount of target was calculated using the 2−ΔΔC T formula.
Protein Extraction and Western Blotting (I-IV)
Triton X-100 extracts were prepared from heart tissue and cell cultures, 
subjected to SDS-PAGE, and electro blotted onto nitrocellulose fi lters (261).
The proteins were detected by immunoblotting using antibodies listed 
in Table 3. The primary antibodies were further detected with horseradish 
peroxidase-labelled secondary antibodies and enhanced chemiluminescence 
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(ECL) as described by the manufacturer (ECL, Amersham Pharmacia Biotech). 
The translation products were quantitated with a gel documentation system 
(Gel Doc 2000, Bio-Rad).
Table 3. List of antibodies used
Primary Antibody Host Isotype Source
BK-1R rabbit Polyclonal Santa Cruz
BK-1R rabbit Polyclonal Own product ref.(364)
BK-2R mouse Monoclonal Transduction Lab
TNF-α mouse Monoclonal Santa Cruz
TNF-R1 mouse Monoclonal Santa Cruz
β-actin mouse Monoclonal Abcam
RhoA mouse Monoclonal Santa Cruz
Control mouse Monoclonal Serotec
Histological and Immunocytochemical Staining 
The frozen human and rat hearts were dissected for immunohistochemical 
stainings using a standard immunoperoxidase method. Briefl y, the slides were 
fi xed with ice-cold methanol. Endogenous peroxidise activity was blocked by 




 in PBS for 10 minutes. After washing the 
slides carefully, they were blocked for 60 minutes with 3% normal serum in 
order to avoid unspecifi c binding of antibodies. The slides were subsequently 
incubated with primary antibodies and diluted in corresponding blocking serum 
overnight at +4 °C. The slides were then washed and a secondary antibody 
was applied. The nuclei were stained with 4´, 6-diamino-2-phenylindole 
dihydrochloride (DAPI) or with hematoxylin and after washing the mounting 
media- fl uorescent or not- added and examined under a normal or fl uorescent 
microscope, depending on the antibodies used.
The samples subjected to immunohistochemical staining, were stained 
using primary antibodies listed in Table 2. The cultured endothelial cells were 
cultured on coverslips until subconfl uent. The cells were incubated in the 
absence or presence of different substances (BK 10-100nM, Icatibant 1μM, 
lovastatin 1nM-100μ, mevanololactone 100μM, Y27632 10μM) or in hypoxic 
conditions. After this the cells were fi xed with 4% paraformaldehyde and kept 
at +4 °C until staining. The primary antibodies were incubated overnight, 
carefully washed, and stained with secondary antibodies. The immunostained 
cells were analyzed using fl uorescent microscopy (Nikon Eclipse E6000 
microscope).
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Culture of Human Coronary Arterial Endothelial Cells
Human coronary artery endothelial cells (HCAEC) were purchased from Promo 
Cell GmbH and used for experiments during passages 4–6. The cells were 
grown in culture media supplemented with growth factors as recommended 
by the manufacture.
The cells were incubated in a humidifi ed incubator at 37 °C with a 5% 
CO2 atmosphere. The medium was changed every second day and experiments 
were performed with subconfl uent cultures. For the hypoxia experiments, the 
cells were changed into a low-oxygen containing incubator (1% or 5% O
2
) and 
grown there for the needed time.
Isolation and Culture of Rat Coronary Artery Microvascular 
Endothelial Cells
Male Wistar rats (300–500 g) were obtained from the Laboratory Animal 
Center of the University of Helsinki. The rats were treated in accordance 
with institutional guidelines, which had been approved by the institutional 
Ethics Committee. The rat myocardium was dissected for perfusion with an 
enzyme solution for 20 minutes and supplemented with BSA for an additional 
10 minutes to facilitate the recovery of separated cells. The perfused tissue 
was cut into small pieces, incubated with the enzyme solution, and then 
fi ltered. The myocardial perfusate and suspension were combined and treated 
with trypsin, CaCl
2,
 and BSA in the perfusion buffer for 30 minutes. The 
cells were collected by centrifugation and resuspended in a culture medium 
supplemented with FBS and appropriate growth factors and antibiotics. The 
cells were identifi ed as RCMCs and cultured in M199 growth media at 37 °C 
under 5% CO
2
. The experiments were performed with ECs of 2nd-6th passages 
in serum-free conditions.
Measurement of NO in Human Coronary Arterial Endothelial Cells
NO production in cultured HCAECs was studied by using 4,5-diamino-
fl uorescein diacetate (DAF-2-DA) as a fl uorescent indicator of intracellular 
NO, as previously described (462). Briefl y, the HCAECs were grown on glass 
coverslips and treated in the presence or absence of lovastatin or in hypoxic 
conditions. The HCAECs were pre-incubated for 30 min with L-arginine, 
pulsed for 10 minutes with DAF-2DA, and washed with PBS. The cells were 
resuspended in PBS containing L-arginine and activated for 10 minutes with 
BK. Intracellular fl uorescence was visualized with a Nikon Eclipse E600 
fl uorescence microscope using excitation at 495 nm and emission at 515 nm.
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cGMP Immunoassay
cGMP was analyzed with the direct cGMP Enzyme Immunoassay Kit 
(Assay Designs, Ann Arbor, MI) according to the protocol described by 
the manufacturer. Briefl y, lovastatin was added to the subconfl uent plates 
and incubated with the cells to obtain a high level of functional BK-2Rs 
in the HCAECs. The lovastatin-treated HCAECs were activated with BK 
for 30 or 60 minutes after which the cells were washed and endogenous 
phosphodiesterase activity was inhibited. The cells were lysed with 0.1 M 
hydrochloric acid and the cell lysate was subjected to overnight acetylation 
and then used in the competitive cGMP EIA kit as recommended by the 
manufacturer. The results were analyzed with a microplate reader (Victor33, 
Perkin Elmer) at 405 nm.
Wound-healing Assay
An in vitro wound-healing assay was performed as previously described by 
Buzza et al. (64). The isolated rat coronary microvascular endothelial cells 
(RCMEC) were cultured on top of thermanox slips in a culture media at 
+37 °C in a humidifi ed incubator with 5% CO
2
. After 2 hours of incubation, 
non-attached cells were removed by washing. The cells were cultured until 
subconfl uent; an endothelial wound was applied to the slip with an appropriate 
sized scrape. The treated slips were then carefully washed to remove detached 
RCMECs and fresh culture media was added in the absence or presence of 
bradykinin and/or icatibant. The thermanox slips were then incubated under 
mild hypoxic culture conditions (5% O
2
) for 24 or 48 hours to induce BK-2R 
expression, and fresh BK and/or icatibant was added at the begining and after 
24 h of incubation. The experiment was terminated by washing the slips 3 
times with ice-cold PBS (including Ca2+/Mg2+) and fi xed with ice-cold 4% 
paraformaldehyde (PFA). The fi xed RCMECs were washed and the cells were 
stained with hematoxylin and photographed with a digital camera attached to 
a Nikon Eclipse E600 microscope.
- / + 9 Polymorphism in Exon 1 of the BK-2 Receptor Gene
Genomic DNA was isolated from human heart tissue using an RNA/DNA Mini 
Kit (Qiagen) and stored in TE buffer (pH 8.5) in aliquots at –20 °C. Isolated 
genomic DNA was subjected to PCR using primers spanning the insertion/
deletion (-/+ 9 bp) site in exon 1 of the BK-2R gene. The PCR was run at T
m
 
= 66 °C for 40 + 1 cycles, and the obtained PCR products were separated on a 
3% MetaPhor agarose gel (BMA).
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-58 T/C BK-2 Receptor Promoter Polymorphism by PCR and SSCP
The genomic DNA was subjected to RT-PCR. The obtained PCR products 
were denatured by heating at 94 °C for 3 minutes in 95% formamide, 10 mM 
NaOH, 0.25% bromphenol blue, and 0.25% xylene cyanol, and then rapidly 
cooled on ice. The denatured PCR samples were mixed with 9 parts of SSCP 
Sucrose Dye and run on a 14% acrylamide/bis (29:1) gel (Bio-Rad). The gel 
was stained with SYBR Gold nucleic acid gel stain (Molecular Probes) for 
30-40 minutes and analyzed with a Gel Doc 2000 gel documentation system 
(Bio-Rad).
11. Statistical analysis
Data are expressed as means +/-SEM. The patient groups showed normal 
distribution when analyzed with the Shapiro-Wilks W-test. Correlation studies 
were performed by using Pearson’s correlation and/or ANOVA statistics. 
Comparisons between the groups were made by using Student’s t-test. 
Statistical signifi cance was accepted as P < 0.05.
12. Results 
BK-1 Receptors in Human Heart Failure
A series of end-stage HF human hearts were analyzed in regard with BK-1Rs 
and compared with control hearts.
A signifi cant increase in BK-1Rs in both mRNA and protein levels in the 
diseased hearts was discovered. The BK-1R mRNA expression was increased 
2.1 -fold in CHD patients and 2.8 -fold in IDC patients compared with control 
hearts.
A low transcript level of BK-1R mRNA was also detected in normal 
myocardias. This was further confi rmed by immunohistochemical staining, 
where a weak staining was detected in intramyocardial vessels also in normal 
hearts.
The protein quantities of BK-1Rs were also more abundant in HF hearts 
compared with control ones. The protein levels were somewhat higher in 
CHD hearts than in IDC hearts, indicating that BK-1Rs are regulated at both 
transcriptional and translational levels, which has previously been suspected 
in HF with other genes (240;428). Moreover, the BK-1R/BK-2R mRNA ratio 
was calculated and there seems to be clear differences between the hearts, thus 
in the normal myocardias 79.000 copies, 32.000 copies in CHD and 25.000 
copies/ 1μg RNA in IDC heart samples were detected.
Intense staining of TNF-α was detected in the diseased hearts and the 
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expression of TNF- α correlated with BK-1R expression in Pearson’s 
correlation test. The immunoreactivity of TNF-α was strongly labelled in the 
intra-myocardial vessels and specifi cally in the endothelial cells, as were also 
the BK-1Rs. Some staining was also detected in the interstitium and in the 
myocardial cells. Furthermore, incubation of human coronary endothelial cells 
with and without recombinant TNF-α, and showed, that BK-1R expression 
was accelerated with the introduction of TNF-α at both the mRNA and protein 
levels.
TNFR-1 staining was intense in the intra-myocardial vessels of the diseased 
hearts and the receptors co-localized with the BK-1Rs in the vessel endothelial 
cells.
BK-2 Receptor Correlation with Age and Polymorphism
The BK-2R mRNA expression was analyzed and a linear regression analysis 
was done, comparing age and receptor amounts in the control hearts. A clear 
positive correlation was found, between age and BK-2R mRNA expression, 
suggesting that transcription of BK-2Rs increases with age in healthy hearts. 
A positive correlation between age and BK-2R mRNA was also found in the 
IDC hearts, but a slightly negative correlation in CHD hearts.
Previously it was suggested that BK-2Rs were regulated on both the 
transcriptional and translational levels in human heart failure (239). By 
plotting the BK-2R levels against the protein levels from both normal and 
failing hearts, a positive, linear correlation was found between the mRNA and 
protein levels, suggesting that BK-2Rs are regulated on the transcriptional 
level and not on the translational level, as previously suggested.
In the promoter region polymorphism -58 T/C, a marked genotypical 
frequency of CC allele was found in the IDC hearts. In IDC hearts 5/7 
possessed genotype CC (71%) compared with 2/6 of this allele (33%) in 
normal hearts. Equal quantities of the TT allele were found in IDC and normal 
hearts, 1/7 and 1/6 (14% and 17%). The dominating genotype in normal hearts 
was TC, seen in 3/6 (50%). The genotypic frequencies in the CHD hearts were 
similar to those in normal hearts. furthermore, the allelic frequencies for -58T/
C polymorphism were 0.58 for the C-allele and 0.42 for the T-allele in normal 
and CHD hearts and 0.79 and 0.21, respectively, in the IDC hearts.
For the -9 bp deletion/insertion SNP in exon 1, all the CHD hearts (100%) 
were homozygous for this deletion (-9/-9). In normal hearts only 1/6 (17%) 
and 2/7 in IDC hearts (29%) were homozygous for this deletion. Seventy-one 
percent of the IDC hearts (5/7) were heterozygous (-9/+9) for the deletion 
and of the normal hearts, 3/6 (50%) were homozygous for the insertion in the 
allele (+9/+9). See Table 4.
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Table 4. Characteristics of human hearts
Induction of BK -Receptors by Lovastatin in Cultured Endothelial Cells
Incubation with lovastatin up-regulated BK-2R mRNA expression in cultured 
human endothelial cells (hCAEC). A dual curve was presented regarding 
the induction of BK-2R expression. At fi rst a rapid and signifi cant (> 11x) 
augmentation of the receptor mRNA was detected after 12-hour incubation 
with lovastatin. The BK-2R receptor expression mRNA declined back to 
the baseline after 24-hour incubation, where after incubating the ECs with 
a concentration of 100nM lovastatin, increasing levels of BK-2R expression 
was presented in the cultured cells during 72 hours of incubation. The level 
of BK-2R mRNA was approximately fi ve-fold greater than in the untreated 
control cells after 72-hour incubation.
Incubating the cells with lovastatin also induced the expression BK-1R 
mRNA. Already, after 6-hour lovastatin incubation the BK-1R expression was 
increased over 23-fold. Also the level of BK-1R expression was declined back 
to control levels during 24-hour incubation. The expression level of BK-1Rs 
also showed a tendency of induction, during the prolonged (72 h) incubation 
of cells with lovastatin, reaching a seven-fold expression level compared with 
the control cells, not incubated with lovastatin.
The increased BK-2 receptor mRNA transcripts were translated into 
protein, shown by Western-Blotting analysis, as the protein levels were also 
up-regulated. The staining of BK-2 receptors was also clearly more intense in 
endothelial cells treated with lovastatin compared to control EC cultures.
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The receptor induction was concentration-dependent and the greatest up-
regulation was obtained with a fairly low lovastatin concentration (100 nM). 
The receptor inducing effect was abolished with higher concentrations (> 1 
μM) of lovastatin, and the highest concentrations of lovastatin were actually 
toxic to the endothelial cells.
To establish the functionality of the inducted receptors, two indirect 
methods were used to show production of NO in lovastatin treated cultured 
hCAECs.
First, in cultured endothelial cells, incubated with lovastatin and at the 
presence of BK, the production of intra cellular cGMP was signifi cantly 
increased. The induction required the presence of BK and lovastatin, thus in 
cells not boosted with BK, or incubated with lovastatin, only a slight elevation 
of cGMP production was detected.
Secondly, the increased production of NO was verifi ed by a fl uorescent 
DAF-2DA stain. Again, incubating the cells with lovastatin and exogenous 
BK, the measured fl uorescence increased in a BK concentration-dependent 
way. The increased production of NO was estimated as three times greater 
than in cells not pulsed by BK. 
The fl uorescence also markedly intensifi ed with increasing the concentration 
of lovastatin.
Mevalonate completely abolished the BK-2R induction in lovastatin treated 
cells, indicating that downstream mediators of the cholesterol pathway were 
involved in the induction of BK-2Rs.
Lovastatin induced the amount of RhoA protein in cultured endothelial cells 
but prevented the activation of RhoA, which was shown by immunocytochemical 
stainings. This was confi rmed by incubating the cells with a specifi c inhibitor 
(Y-27632), of Rho-associated proteins (ROCK). By inhibiting ROCKs, a time-
dependent increase in the expression of BK-2R mRNA was detected, which 
was similar to the results presented with lovastatin treated cells.
Incubating the ECs together with lovastatin and a specifi c COX-2 inhibitor 
(NS398), the BK-2R induction was abrogated. The incubation of mere COX-2 
inhibitor had no effect on the BK-2R expression.
Induction of BK-2 Receptors in Hypoxia
In mild hypoxic conditions (5% O
2
) the level of both BK-2R mRNA and protein 
expression was signifi cantly induced compared with cells grown in normoxic 
conditions. The amount of BK-2R mRNA was time-dependently induced in 
mild hypoxic conditions. In contrast, severe (1% O
2
) hypoxia clearly reduced 
the BK-2R expression.
The hypoxic induction was abolished by incubating the cells with icatibant, 
a specifi c BK-2R antagonist. The protein expression was also induced in mild 
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hypoxic conditions and where icatibant again abrogated the BK-2R induction.
Functionality of the receptors was verifi ed by DAF-2DA immunocytochemical 
fl orescent stainings. In hypoxic cells the increased NO production was 
shown to be approximately three times greater than in normoxic cells. The 
NO production was induced in hypoxic cells but a clear difference was also 
detected in cells incubated with or without additional BK in mildly hypoxic 
chamber, where additional BK increased the amount of NO detected.
These in vitro results were then compared with in vivo rat experiments. 
Rats subjected to myocardial infarction by LAD ligation, showed an 
increased number of BK-2Rs in the endothelium of the myocardial vessels 
at the infarct border zone, suggesting that the BK-2Rs were also induced in 
vivo by hypoxia. To address this hypothesis, a “wound healing” assay was 
conducted, previously described by Buzza et al. (64). This experiment showed 
that hypoxic conditions induced endothelial cell migration, which was further 
augmented by additional BK. The migratory effects were almost abrogated 
by incubating the hypoxic cells with icatibant. Proliferation of the migrating 
cells was also detected, thus the cells expressed Ki-76, a commonly used 
proliferation marker (data not shown).
Hypoxia induced functionally active BK-2Rs in a BK-K-2R-NO -dependent 
way. The induction of migration and proliferation in hypoxia was increased by 
BK and abrogated by icatibant.
The main results
In human end-stage HF:
• The BK-1R expression is increased in the intra-myocardial vessels.
• The BK-1R induction is accompanied with TNF-α induction and TNFR-1 
co-localized with BK-1Rs.
• The expression of BK-2Rs increases with age in healthy human myocardias.
• The CC -allele of -58 T/C BK-2R SNP is more abundant in IDC hearts, 
compared to normal or CHD hearts.
In cultured endothelial cells:
• Lovastatin treatment increases the expression of functional BK-2Rs in a 
time and concentration dependent way. The induction can be abrogated by 
mevanolate.
• The induction of BK-2Rs in statin treated cultures is also inhibited by a 
COX-2 inhibitor, NS398.
• Hypoxia induces BK-2R expression in cultured cells. The induction of 
receptors, NO production but also angiogenesis was clearly increased in 
hypoxic cultures pulsed with BK. Icatibant abrogated all these effects.
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13. Discussion
In the present study, I have focused on understanding the function and 
regulation of BK receptors in the pathophysiology of human heart failure. 
HF is a clinical syndrome caused by different cardiovascular diseases and the 
kinin system seems to be implicated in its pathogenesis. Kinins are powerful 
bioactive autacoids that have been shown to reduce the myocardial preload 
and oxygen consumption, thus improve the cardiac metabolism and function. 
Kinins exert their biological functions by activating specifi c kinin receptors. 
In particular, BK activated BK-2Rs are widely accepted as cardioprotective 
molecules, as they mediate both vasodilatory, antifi brotic, and antiproliferative 
effects via an increased production of NO, EDHF and PGI
2
. BK is also known 
to counteract endothelial dysfunction, a phenomenon involving a decreased 
expression of eNOS with subsequent reduction in NO bioavailability, present 
in the hypoxic myocardium during HF.
The role of BK-1Rs in heart diseases and especially in HF has remained 
vague. The differences in kinin signaling in normal and failing hearts may 
depend on either kinin concentrations, kinin degrading enzymes, or on the 
regulation of BK-receptors, that may account for kinin mediated effects in 
endothelial cells, myocytes, and fi broblasts.
BK-1Rs and Infl ammation
Kinins are proinfl ammatory peptides acting as local hormones and kinins induce 
the release of endothelium derived relaxing factors. Many of these effects are 
mediated through activation of BK-2Rs but in pathological conditions, also 
BK-1Rs mediate the cardiovascular responses of kinins.
Various studies show an induction of BK-1Rs in pathological conditions, 
such as tissue trauma, infl ammation, or anoxia. Indeed, it has been suggested 
that BK-1Rs partly account for the initiation of infl ammation (132;242). 
Moreover, the level of infl ammatory cytokines is increased in HF, which are 
known to induce the expression of BK-1Rs (256). The role of BK-1Rs in 
cardiovascular diseases derives mainly from animal studies and has remained 
controversial (53;242;292). 
In the present study, we showed an increased expression of BK-1Rs in 
human end-stage failing hearts, implying that induction of BK-1Rs refl ects the 
pathological progression of HF and ongoing infl ammation. Previous studies in 
hypertensive rats show that up-regulation of BK-1Rs seems to be associated 
with the transition from compensated LV hypertrophy to heart failure, with the 
onset of myocardial fi brosis and with the development of diastolic dysfunction 
(240;452).
In previous study, Kuoppala et al showed low levels of BK-2Rs in the 
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LV of end-stage HF patients and the study detected a signifi cant increase in 
fi brosis in IDC hearts compared with normal hearts (239). In the present study 
we showed increased levels of BK-1Rs, as well as an increased ratio of BK-
1R/BK-2R in the myocardium of the HF hearts, suggesting that infl ammation 
accompanies the increased level of fi brosis in these failing hearts. This has 
previously been addressed in human lung fi broblasts, where induction of BK-
1Rs activated fi brogenesis. Moreover, in stenotic aortic valves, a signifi cant 
induction of BK-1Rs was detected in the diseased valves compared to control 
valves. Myofi broblasts, cultured from the stenotic valves, were also more 
susceptible towards TNF-α induced BK-1R up-regulation (181;293). 
Our study also showed a correlation of the increased TNF-α levels and 
TNFR-1 expression in the intra-myocardial coronary vessels with induced 
BK-1R levels as well as co-localization of BK-1 and TNFR-1s. The results 
imply that an infl ammatory context in HF is a regulator element in BK-1Rs 
expression.
Whether the upregulation of BK-1Rs in the failing human hearts refl ects 
increased production of cytokines or a compensation of the BK-2R down-
regulation can presently not be answered. However, knockout studies have 
shown that BK-1Rs are up-regulated in the heart of BK-2R knockout-mice and 
they can takeover some of the hemodynamic properties of BK-2Rs, suggesting 
that the BK-1Rs can take a compensatory role at least in the absence of BK-
2Rs, and thus be cardioprotective (124).
The highest level of BK-1Rs and the lowest of BK-2Rs were detected in 
IDC hearts, suggesting that the etiology of HF and BK-receptor regulation 
are interrelated. The observation that the level of fi brosis in the end-stage 
HF patients was higher in the IDC hearts compared to CHD hearts supports 
this notion (239). The differences in receptor levels between CHD and IDC 
may also be explained by differences in the genetics, a notion supported by 
previously observed differential expression of several genes in coronary 
arteries from CHD and IDC patients (388).
Deletion of BK-1Rs does not, under basal conditions, affect cardiovascular 
function or growth and BK-1R knockout-mice do not develop hypertension 
or myocardial hypertrophy nor HF (242;352), suggesting that BK-1Rs have a 
diminutive role on cardiovascular regulation under normal situations. On the 
other hand, animal models and human artery in vitro studies have shown that 
BK-1Rs can regulate vascular tone (230;286;487). Under healthy conditions, 
the level of BK-1Rs is undetectable or extremely low in human myocardias. 
Our perception of a low BK-1R level also in control hearts, suggests that BK-
1Rs may exert some function in the normal cardiovascular regulation. It may 
also merely refl ect a normal aging process, previously suggested in animal 
studies (225). 
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BK-2Rs and Aging
In our study, the level of BK-2Rs correlated positively with age in healthy 
hearts, suggesting that healthy human heart adapts to ageing or senescence by 
inducing BK-2R expression.
The association between BK-2Rs and senescence has been recently 
reported in bovine endothelial cells, where BK dose dependently protected the 
cells from ROS induced senescence through pathways involving BK-2R and 
NO (336). In addition, in a report from Kakoki et al, BK-2R knockout-mice 
displayed a slightly accelerated ageing phenotype. The ageing phenotype was 
strongly promoted when the BK-2R knockout was combined with diabetes 
(212). These results strongly suggest, that BK-2Rs are associated with 
senescence and protect against its damaging effects.
We also reported a positive correlation between BK-2R mRNA and age in 
IDC hearts, where as the correlation was negative in CHD patients. This can 
refl ect the some what older patient material of the CHD group, but may again 
also imply disease-dependent regulation of BK-2Rs or a genetic variation.
Contradictory results were reported from animal studies, where unchanged 
levels of BK-2R mRNA were detected, from young and old rats. Whether this 
refl ects normal ageing process in rats or differences in cellular composition in 
ageing hearts can not be answered. A discrepancy was detected in the study by 
Kintsurashvili et al, between the gene expression and protein translation, thus 
in old rats the BK-2R protein levels were two-fold lower as compared to young 
ones (225). The differences between gene expression and protein translation 
in the study suggests, that BK-2Rs are regulated post-transcriptionally, which 
was also our fi nding in the end-stage human hearts. 
BK-2 Receptor Polymorphism
Racial differences in survival outcomes, point to genetics in the predisposition 
of HF and to date two BK-2R polymorphisms have been connected to 
hypertension and HF (119). In our studies the C-allele in -58 T/C SNP was 
signifi cantly more abundant in IDC patients which could account for the 
development of HF and also the lower level of BK-2Rs detected in IDC 
patients. The age-related up-regulation of BK-2Rs was impaired in IDC hearts, 
suggesting that high frequency of the C-allele, detected in IDC hearts, might 
relate to the lower BK-2Rs levels detected. 
As for the +9/-9 insertion/deletion SNP, all of our CHD hearts possessed 
the -9 deletion. None of the diseased hearts and 33% of the control hearts were 
homozygous for the +9 insertion, suggesting that the known genetics of +/-9 
was not associated with down-regulation of BK-2Rs in our patients. 
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BK-2Rs and Statins
As the endothelium is the major contributor of kinin receptor function, we have 
also studied endothelium and factors modulating kinin receptors in endothelial 
cells. In many clinical studies, statins have reduced mortality in CHD patients. 
Subclass analyses have suggested that statins might also be benefi cial in HF 
patients without CHD, though these results have not been confi rmed. 
Our novel results show that lovastatin is able to induce both BK-receptors 
types in cultured human endothelial cells. The induction of BK-2Rs is 
concentration-dependent and clinically-relevant doses (lovastatin 80mg) seem 
to correlate with the greatest BK-2R induction. The effects were abrogated 
by mevanolate, implying that the down-stream mediators of cholesterol 
biosynthesis pathways are involved. More specifi cally, it involved inhibition 
of RhoA-Rho kinase-mediated downstream signaling pathways, previously 
been shown to have an important role in cellular functions in the pathogenesis 
of cardiovascular diseases. Rho-kinase up-regulates several molecules that 
accelerate infl ammation and fi brosis, and down-regulates eNOS (247;434). 
The present study showed that exogenous BK accelerated the up-regulated 
BK-2R expression and increased NO production in lovastatin-treated human 
ECs. A direct regulatory link between BK-2R and eNOS has been shown, 
where the level of eNOS and also production of NO depend on the level of 
BK-2R. (23;509).
In a dog model BK induced NO production in renal and coronary arteries, 
which was attenuated with HF dogs and retrieved by simvastatin.(4;451). 
Moreover, the BK induced relaxation in rat mesentery arteries was enhanced 
by simvastatin, which resulted from inhibition of RhoA and attenuation of 
the vascular contractility through augmenting the endothelial NO production 
in mesenteric arteries (408). Unfortunately, no data concerning BK receptors 
was reported.
By reducing the prenylation of isoprenoids, statins inhibit Rho–kinases, 
accelerated by several infl ammatory stimuli such as IL-1β and angiotensin 
II (186). In our studies, the statin effect on BK-2Rs was reversed by both 
mevanolate and icatibant and mimicked by Rho inhibitor, indicating the 
involvement of Rho in the signal transduction leading to BK-2R expression.
The results suggest that BK increases NO production via activating BK-2Rs 
and eNOS in statin-treated endothelial cells. This involves the RhoA-Rho-
kinase pathway, thus implying that some of the pleoitropic effects of statins 
may be explained by induction on BK-2Rs, at least in endothelial cells.
The relevance of BK-1R induction by lovastatin remains unclear. Statin 
treatment attenuates infl ammatory signaling pathways, implying another 
mechanism for the induction of BK-1Rs, in statin treated cells.
It has previously been shown in a murine model that ACE inhibitors can 
up-regulate functional BK-1Rs, suggesting that also BK-1Rs have benefi cial 
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cardiovascular effects in the BK-BK-R signaling cascade, without infl ammation 
(286). Moreover, deletion of BK-2R has been shown to induce the expression of 
BK-1Rs, suggesting a role for these receptors in the cardiovascular regulation 
(213).
Confl icting results were reported recently, where disruption of BK-
2Rs resulted in early development of LVH and down-regulation of eNOS. 
The effects were abrogated by simvastatin and the authors concluded that 
simvastatin reversed the effects by activating the myocardial eNOS and MAP 
kinase (339). Moreover, no differences in BK-1R expression were detected 
between wild type or BK-2R knockout mice nor had simvastatin treatment 
any effect on the BK-1R expression. The discrepancies between these studies 
can relate to differences in species studied, to different knockout variants used 
or differences in experimental set-ups.
The exact mechanisms, by which statins induce BK-receptors, is presently 
not known, although a direct gene activating effect may be involved. In the 
light of former studies our in vitro results suggest that in heart failure, patients 
might benefi t from statin treatment through induction of BK-2Rs resulting in 
increased NO production.
BK-2Rs and COX-2
Of the two known COX-isoforms, COX-1 is traditionally viewed as the 
constitutive enzyme, responsible for the production of the physiological 
amounts of prostaglandins needed. COX-2 is induced by various infl ammatory 
stimuli and cytokines, and considered as a mediator of infl ammation and 
pain.
COX-2 expression can be found both in the vascular ECs and SMCs and 
in the ECs, it mainly forms prostacyclin (PGI
2
), which induces vasodilation. 
Prostacyclin is an important secondary mediator, often released by kinins 
from the endothelium, which stimulates cyclic AMP in vascular smooth 
muscle cells leading to vasorelaxation. Prostanoid formation occurs in many 
cell types, which possess kinin receptors.
Statin treatment has previously been shown to inhibit the generation of 
COX-2-derived prostanoid production and also down-regulate COX-2 
expression in both endothelial and vascular smooth muscle cells (98). Recently 
several opposing reports have been published, where statins induce COX-2 
expression and PGI
2
 formation in human endothelial cells through inhibition 
of Rho (105;288).
In our study, the induction of statin treatment on BK-2R expression was 
reversed by COX-2 inhibitor (NS398). Moreover, no effect on BK-2Rs was 
detected when incubating the cells merely with a COX-2 inhibitor, nor could 
we detect any differences in COX-1 expression, suggesting a direct link 
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between BK-2R and COX-2 pathways in endothelial cells.
A connection between BK-2Rs and COX-2 has previously been suggested 
by Marceau et al. In this study diclofenac induced BK-2R down-regulation in 
rat hearts, although suspected, they could not show a feed-back mechanism 
between COX-2 and BK-2Rs (281).
Previous studies reported, that exogenous BK was able to induce COX-2 
expression, in different cell types (55;344). Moreover, in rat aortic VSMC, 
BK induced the expression of COX-2, and the effect was reversed by icatibant 
and L-NAME, but not by a BK-1R inhibitor. (379). Also, in rabbits infusion 
of COX-2 inhibitor (diclofenac) induced BK-2R down-regulation in the rabbit 
heart (281). In a recent study, the positive post-conditioning effect of BK 
was abolished by a COX-inhibitor, which was thought to relate to decreased 
production of PGI
2
 (349). COX-2 induction by BK can be blocked by 
icatibant or L-NAME, suggesting, that at least in ECs, the induction of COX-
2, involves activation of BK-2 receptors and eNOS. Several studies show, 
that RhoGTPases are involved in the regulation of COX-2, although the exact 
mechanisms are still not clear.
Thus, it can be suggested that, in lovastatin treated endothelial cells, BK 
induces BK-2Rs, increasing the production of NO and PGI
2 
via eNOS and 
COX-2, respectively, leading to increased vasodilation in the vasculature. 
Whether the COX-2 effect relates to increased prostacyclin production, to 
decreased production of contracting prostanoids or to some other mechanism, 
can not be addressed.
It can also be speculated, whether the negative cardiovascular effects of 
COX-2 inhibitors observed in large clinical studies, partly relates to the down-
regulation of BK-2Rs. 
Endothelial Hypoxia and Preconditioning 
Hypoxia is a common factor in cardiovascular diseases, regardless of etiology. 
Hypoxia stimulates BK production and the expression of eNOS is known to 
increase in hypoxic conditions. Several studies focusing on the effects of 
BK in both animals and humans exists, but again the signifi cance of BK-
receptors in hypoxia is not conclusively studied. In our in vitro studies mild 
hypoxia induced functional BK-2Rs in hCAECs, but also in coronary artery 
smooth muscle cells (CASMC), and the effect was reversed by icatibant. 
This might give a mechanistical explanation for pre- and postconditioning, 
as BK is known to be one of the main effector molecules in preconditioning. 
In experimental models, short intervals of repeated hypoxia are known to 
be benefi cial to the heart, improving the outcome after induced myocardial 
infarction (323). Postconditioning also augments the deleterious effects 
induced by reperfusion, and activation of BK-BK-2Rs is involved in this 
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cardioprotection (350). Hence, our results from hypoxic ECs, might refl ect 
the protection seen in pre-and postconditioning. Indeed, the cardioprotective 
effects of preconditioning are abolished in BK-2R knockout mice and BK 
induces and icatibant attenuates the cardioprotective effects in a rabbit model 
of preconditioning (475). Moreover, in a recent study, postconditioning or 
intermittent BK infusion was shown to protect the myocardium and involve 
activation of COX-2 and subsequent PGI
2
 formation (349). 
We showed that hypoxia also induced migration of endothelial cells, which 
was abrogated by icatibant, suggesting a role for BK-2Rs in angiogenesis. 
This is consistent with previous results in which BK-2Rs were shown to 
transactivate VEGF receptors (KDR/Flk-1) and to induce tube formation 
in hCAECs (310). Similar results have been shown in mouse hearts, where 
angiotensin II and hypoxia signifi cantly increased angiogenesis via AT-2Rs 
and the effects were BK-BK-2R and eNOS -dependent (322). Enalapril was 
also able to induce sprouting in hypoxic mouse hearts through both BK-1Rs 
and BK-2Rs, requiring the presence of both BK and BK-2Rs. Thus, BK and 
other vasoactive molecules can promote angiogenesis in hypoxic mouse hearts 
by activating BK-2Rs (384). 
Our results showed that under hypoxic conditions, induction of BK-2Rs in 
cultured ECs was clearly attenuated by exogenous BK, which also increased 
the basal NO production.
Our results from rats, recovering from myocardial infarction, showed an 
induction of BK-2Rs in the endothelium of vessels forming at the border zone 
between the scar tissue and healthy myocardium, i.e. where potential ischemia 
augments BK formation and BK-2R expression and enhances angiogenesis. 
This further implies that the pathophysiological mechanisms activated during 
ischemic injuries also involve activation of the kinin receptor system.
Supporting our results are also the observations, that ACE inhibitor 
treatment or tissue kallikrein gene delivery increased myocardial capillary 
density and accelerated cardiac remodeling in SHRs in a BK-2R-dependent 
way (48;164). 
Our results show that mild hypoxia induces the expression of functional 
BK-2Rs capable of increasing NO production and that BK-2Rs play a role 
in angiogenesis and EC migration in hypoxic conditions. There are also 
indications that PGI
2
 via COX-2 induction might enhance the cardioprotective 
effects of kinin system.
In cardiovascular diseases, such as hypertension and CHD, which often 
lead to clinical HF, the cardioprotective role of BK-2Rs has been shown.
BK and BK-2Rs oppose endothelial dysfunction and contribute to 
angiogenesis(132;322). The kinin system decreases preload and cardiac output, 
thus improving myocardial metabolism and performance. BK also exerts a 
unique pattern of injury limiting actions in preconditioning (444;475). It exerts 
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cardioprotective effects when administered prior to the onset of ischemia, 
participates in early preconditioning, and is also an important factor in late 
preconditioning (235;402;468). ACE inhibitors and NEP inhibitors increase 
bradykinin concentration in the myocardium, thus they increase the protective 
effects of BK in ischemic diseases (325;446;483). Exogenous bradykinin, 
augmenting endogenous BK levels or activating BK-2Rs, possibly also BK-
1Rs, could have an impact on the treatment of ischemic heart diseases.
From previous results hypothesis can be made that during the progression 
from compensated left ventricular hypertrophy to fulminate heart failure, the 
heart tries to compensate for ongoing changes by increasing the number of 
BK-2Rs, but in the end fails to do so and clinical HF develops, accompanied 
by diminished BK-2R levels and increased BK-1R levels(239;260). Is the 
diseased myocardium unable to react to BK and induce the BK-2Rs, in end-
stage hearts, where the induced myocardial growth is accompanied with 
diminished NO production and unbalanced Ang II secretion. Or, are there 
other factors contributing to the down-regulation of BK-2Rs and progression 
of HF, can not be answered. Also, wheater the induction of BK-1Rs is a 
compensatory mechanism towards the down-regulation of BK-2Rs or a 
response to the infl ammatory cascades activated, are not known.
The relevance of BK-1Rs in heart failure is still debatable. If the up-
regulation of BK-1Rs in end-stage HF is cardioprotective, the induction of 
BK-1R could represent compensatory effect for BK-2R down-regulation. 
Several studies show, that BK-1Rs take over the protective effects of BK-
2Rs, when the BK-2R are genetically or pharmacologically deleted. There are 
also several contradictory reports, were the induction of BK-1Rs accompanies 
activation of cardiotoxic pathways and progression of the cardiovascular 
disease.
Clinical Implications
Statin treatment has been shown to have several cholesterol-independent 
mechanisms that counteract endothelial function. Inhibition of the Rho-Rho 
kinase pathway partly accounts for the benefi cial pleoitropic effects of statins 
and relates to the induction of BK-2Rs, thus improving the vascular endothelial 
dysfunction.
The benefi cial cardiovascular effects of ACE inhibitor treatment are 
generally considered to arise from the prevention of BK degradation and the 
induction of BK-2Rs thus promoting vasodilation in endothelial cells, and 
inhibition of myocyte hypertrophy. Blockade of the BK-2R, partially prevents 
the cardiovascular benefi ts of ACE inhibition in different disease models, 
demonstrating the pharmacological relevance of bradykinin signaling in 
cardiovascular disease (263). 
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As BK in degraded by both ACE and NEP, simultaneous inhibition prevents 
the degradation more effi ciently than ACE inhibition alone, leading to 
increased plasma and tissue concentrations of BK (40). The most extensively 
studied dual inhibitor, omapatrilat, has been studied in human heart failure, 
and it has shown superior results in HF when compared to ACE inhibitors. 
Unfortunately severe angioedema, in higher frequencies in patients receiving 
omapatrilat, has been reported and because of these serious concerns, it has 
not been approved for the treatment of HF (19). 
Several chemical and physiological factors regulate the BK-R expression. 
Moreover, kinins are known to affect most pathological conditions leading 
to LVH and HF. Actions intensifying either BK and/or BK-2Rs, might give 
additional tools for the treatment of HF. The molecular mechanisms leading 
to HF are not clear, and among other pathways, the kinin system and factors 
regulating it, need more studies, in order to fi nd therapeutical drugs for 
treating HF.
14. Summary and Conclusions
1. In the human end-stage heart failure functional BK-1Rs were signifi cantly 
increased in the intra myocardial coronary vessels. This induction was 
accompanied by accumulation of TNF-α and the receptors co-localized 
with TNFR1 in the myocardial vessels, referring that the induced BK-1Rs 
relate to infl ammation and increased fi brosis in heart failure. This implies 
that infl ammation regulates the expression of BK-1Rs in human HF.
Because the known cardioprotective actions of BK are mediated via BK-
2Rs, whereas BK-1Rs are induced by tissue damage, these results suggest 
that the decreased BK-2R levels in the end-stage HF, may leave the hearts 
vulnerable to damages, and increases in the BK-1R expression and activity 
may represent a compensatory reaction in the diseased hearts.
2. The expression of BR-2Rs increased with age in healthy human hearts, 
which suggests that the human heart adapts to age-related changes in heart, 
by up-regulating the expression of cardioprotective BK-2Rs.
From previously known polymorphisms, the 9bp insertion/deletion SNP 
didn’t seem to have a role in the progression of HF. The C-allele of -58 T/C 
SNP was more abundant in the IDC patients, which may account for the 
lower BK-2R mRNA levels detected and the development of HF. 
Our results also suggest that different signaling cascades are activated 
in CHD and IDC patients.
14. SUMMARY AND CONCLUSIONS
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3. Lovastatin treatment clearly increased the amount of functional BK-2Rs 
in the endothelial cells, involving Rho-Rho kinase pathways, previously 
shown to have an impact on the progression of cardiovascular diseases. 
Thus, some of the benefi cial cardiovascular effects of statins may relate to 
increased number of BK-2Rs in the endothelium.
A connection between COX-2 expression and BK-2R was also 
presented. Our results arose an intriguing question of whether the use of 
COX-inhibitors and the increased risk of myocardial infarction, relates to 
down-regulation of BK-2Rs. 
Our results suggest that HF patients benefi t from statin treatment also 
via induction of BK-2Rs and increased NO production, thus improving 
the endothelial function. We also suggest that by decreasing the level of 
BK-2Rs, COX-inhibitors promote dysfunction of the endothelium and 
together with increased thrombosis activation, may worsen the outcome 
of HF patients.
4. Mild hypoxia induced the expression of BK-Rs in cultured endothelial cells. 
Exogenous BK induced the expression of BK-2Rs and also the migration 
of endothelial cells in hypoxic conditions. This migration was abrogated by 
inhibiting the BK-2Rs, suggesting a role for BK-2Rs on EC migration and 
proliferation in hypoxic conditions. The angiogenesis promoting effects 
were also shown in an infarct model, where BK-2Rs were localized at the 
infarct border zone, where hypoxia likely exists. Hypoxia induces BK and 
BK-2R formation and NO production, which promote angiogenesis and 
the healing of the myocardium.
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